

Award Number: DAMD17-97-1-7070

TITLE: The Use of a New Technique to Study DNA Methylation in Breast Cancer

PRINCIPAL INVESTIGATOR: Hao Peng X. Duffy, Ph.D.

CONTRACTING ORGANIZATION: North Shore University Hospital  
Manhasset, New York 11030-3801

REPORT DATE: October 2000

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
Distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010327 077

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE October 2000	3. REPORT TYPE AND DATES COVERED Final (1 Oct 97 - 30 Sep 00)		
4. TITLE AND SUBTITLE The Use of a New Technique to Study DNA Methylation in Breast Cancer			5. FUNDING NUMBERS DAMD17-97-1-7070	
6. AUTHOR(S) Hao Peng X. Duffy, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) North Shore University Hospital Manhasset, New York 11030-3801  E-MAIL: hduffy@nshs.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES  This report contains colored photos				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; Distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) The mechanisms of breast cancer development are incompletely understood. A reasonable hypothesis is that the evolution of this disease is caused by various genetic, and non-genetic factors. These may occur in multiple steps which eventually precipitate genetic lesions; such as mutations, or deletions. One causative factor may be imbalanced DNA methylation. A new technique, Methylation Differential Display (MDD), has been developed to explore DNA methylation patterns in breast cancer. BR50 was one of the hypomethylated DNA fragments isolated by MDD. Further study of BR50 has led to the discovery of a novel gene, TSP50. The TSP50 gene product is homolog to several human serine proteases which indicates that it may encode a serine protease like protein. Northern analysis of sixteen different types of normal human tissues suggest that TSP50 was highly, and specifically expressed in human testes, which indicates that it might possess a unique biological function(s) in that organ. Methylation status analysis in normal human testes and other tissues showed a correlation between DNA methylation and gene expression. Most importantly, RT-PCR analysis of eighteen paired breast cancer tissues found that, in 28% of the cancer samples, the TSP50 gene was differentially expressed. In addition, the activation was located in the epithelia breast cancer cells.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 34	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover..... 1

SF 298..... 2

Introduction..... 4

Body..... 4

Key Research Accomplishments..... 11

Reportable Outcomes..... 11

Conclusions..... 11

References..... 12

Appendices..... 20

## The Final Report for Award Number DAMD17-97-1-7070

### The Proposal Title: The Use of a New Technique to Study DNA Methylation in Breast Cancer

#### I. Introduction

The overall goal of the proposal funded by the Department of Defense Breast Cancer Research Program, was to study DNA methylation in human breast cancer development, and use differentially methylated genomic DNA fragments (DMGFs) to search for breast cancer related genes. To reach this objective, our specific aims were:

1. to develop and refine a new technique, Methyl Differential Display (MDD), to study the role(s) of DNA methylation in human breast cancer development.
2. to apply this technique to isolate genomic markers which detect altered DNA methylation patterns in breast cancer cells.
3. to search for new types of oncogene(s) whose expressions were under the control of DNA methylation mechanisms by DMGFs.
4. to determine the biological function(s) of candidate gene(s).
5. to search for the candidate gene's potential use in clinical diagnosis and prognosis.

In the past three years, our studies progress has included the following achievements: 1). To develop the MDD technique; 2). To isolate DMGFs by employing MDD; 3). To discover a novel gene, *TSP50*, by a hypomethylated DMGF, *BR50*. 4). To analyze the *TSP50* gene's biological characteristics and its breast cancer related features. Our research found that a. The *TSP50* gene was specifically expressed in human testes; b. It could encode a new serine protease; c). Its expression could be regulated by DNA methylation; d). It was abnormally activated in some breast cancer patients; and e). Its transcripts were located in the cytoplasm of the neoplastic epithelia cells in breast tissue.

In the following paragraphs, a detailed report of our achievements will be presented. The overall findings related to the *TSP50* gene have been published in *Cancer Research*, and presented during the American Association for Cancer Research (AACR) annual meeting for the year 2000 (see Appendix).

#### II. Body

This section includes two parts, the experimental procedures which were employed for this research and the major results obtained.

##### II.A. Experimental Procedures

**II.A.1. DNA from human cancer biopsies.** Dissected human breast and ovarian cancer tissues (tumor and matched normal) were immediately frozen in liquid nitrogen, and stored at  $-70^{\circ}\text{C}$ . DNAs were isolated from those tissues by the phenol extraction method (1).

**II.A.2. MDD.** 1-2  $\mu\text{g}$  of DNA (tester) isolated from human breast cancer biopsies and their matched normal DNA (driver) were cleaved with *Msp* I (20 U/ $\mu\text{l}$ ) (Boehringer Mannheim), and *Mse* I (20 U/ $\mu\text{l}$ ) (New England Biolabs, Inc.) in a 50  $\mu\text{l}$  reaction for 3 hours. To prepare tester and driver master amplicons, the *Msp* I and *Mse* I digested tester and driver genomic DNAs were ligated to 1.5  $\mu\text{g}$  MSA24-mer and 0.75  $\mu\text{g}$  MSA12-mer (2); these were the first pair of oligonucleotide linkers which only recognize the ends generated by *Msp* I. The procedures for amplicon preparation were as described (2,3). The DNA amplicons were then purified by phenol, phenol/chloroform extraction. To remove the first set of linkers from the driver amplicon, 80  $\mu\text{g}$  of driver amplicon DNA was digested with the *Msp* I enzyme (10 U/ $\mu\text{l}$ ). To change the tester master amplicon DNA linkers, 5  $\mu\text{g}$  of tester master amplicon was digested with *Msp* I (20 U/ $\mu\text{l}$ ) and ligated to 0.6  $\mu\text{g}$  of MSB24-mer, and 0.3  $\mu\text{g}$  of MSB12-mer, these were the second set of oligonucleotide linkers. Subtractive hybridization was performed as described (2). The first round of difference products (DP1) were amplified as described (2). To prepare the second round of subtractive hybridization, 3  $\mu\text{g}$  of DP1 was digested with the restriction endonuclease *Msp* I (20 U/ $\mu\text{l}$ ). To put a new set of linkers on DP1, 0.1  $\mu\text{g}$  of DP1 was mixed with 0.6  $\mu\text{g}$  of MSC24-mer, and 0.3  $\mu\text{g}$  of MSC12-mer. Another round of subtractive hybridization/PCR amplification was repeated. Difference product 2 (DP2) usually contained several individual DNA fragments when electrophoresed on a 2% agarose gel. The individual DNA fragments were purified by DNA gel extraction kit (Qiagen Inc.), and subcloned into pUC118 vector, which was linearized by the restriction endonuclease *Acc* I, and transformed into *E. Coli* (DH5 $\alpha$ ). Twelve cloned inserts were chosen to be amplified, from which different sized probes were selected for master amplicon southern blotting, and human genomic DNA southern blotting.

**II.A.3. Amplicon DNA southern blot.** The first round of positive probe screening was performed with amplicon DNA southern blots. Non-Radiation Southern Blot and Detection Kits (Genius<sup>TM</sup>) were purchased from Boehringer Mannheim. Probe labeling and detection followed the instructions of the manufacturer. 2-3  $\mu\text{g}$  of tester and driver amplicon DNA were electrophoresed on a 2% agarose gel, and blotted to positively charged nylon membranes (Boehringer Mannheim). For prehybridization, the membranes were placed at 68  $^{\circ}\text{C}$  for 2-4 hours in solutions containing 6 X SSC, 5 X Denhardt's solution, 0.5% SDS, 0.1 M EDTA, and 50  $\mu\text{g}/\text{ml}$  of salmon sperm DNA. Under the same conditions, the probes were added, and hybridized to the membranes overnight. The membranes were then rinsed three times with 2 X SSC, 1 X Blot wash (12 mM  $\text{Na}_2\text{HPO}_4$ , 8 mM  $\text{NaH}_2\text{PO}_4$ , 1.4 mM  $\text{Na}_4\text{P}_2\text{O}_7$ , 0.5% SDS) at 68  $^{\circ}\text{C}$ , and further washed three times (30 minutes each) with the same buffer at 68  $^{\circ}\text{C}$ . Next, the membranes were equilibrated in buffer A (100 mM Tris.HCl, 150 mM, pH 7.5) and transferred into buffer B (2% block reagent in buffer A) which was incubated at room temperature for one hour. The membranes were then washed 2 times for 15 minutes with buffer A, and equilibrated in buffer C (100 mM Tris.HCl, 100 mM NaCl, 10 mM  $\text{MgCl}_2$ ). Before the membranes were exposed on Kodak X-OMAT film for one hour, they were rinsed in lumi-P530 for 1 min and kept in a plastic sheet protector.

**II.A.4. Genomic DNA southern blot.** The positive probes confirmed by amplicon DNA

southern blot experiments were tested further by human genomic DNA southern blotting. Genomic DNAs isolated from tumor tissues, and their respective matched normal tissues, were digested with *Msp* I (20 U/ $\mu$ l), and electrophoresed on 1.5% agarose gels, which were then transferred to Hybond N-membranes (Amersham, Arlington Heights, IL). These membranes were exposed to UV light to immobilize the DNA. The probes for the southern blot were labeled with High Prime DNA labeling kits (Boehringer Mannheim) following the instructions of the manufacturer. The procedure for hybridization and blot wash were the same as in the Amplicon DNA southern blotting section.

**II.A.5. DNA sequence and chromosome assignment.** The pUC118 plasmid containing the candidate DP2 fragment was sequenced using the Ampli-Cycle sequencing kit (Perkin-Elmer), under conditions described by the manufacturer. Chromosome assignment for the candidate DP2 fragment was determined by genomic southern blotting of the *Hind* III digested monochromosomal human/rodent somatic cell hybrid mapping panel #2 (NIGMS Human Genetic Mutant Cell Repository) while it was used as a probe. Fine chromosome mapping was performed with Genebridge 4 Radiation Hybrid Panel (Research Genetics, Inc.) by PCR amplification(4).

**II.A.6. Human genomic DNA library screening.** A human placenta genomic phage library, EMBL3 SP6/7 (Clontech, Inc.), was used for cloning a longer genomic fragment containing the candidate fragment. Phage infection procedure was based on the instructions supplied by the manufacturer.  $2 \times 10^6$  plaques were evenly distributed on 20 plates (150 X 15 mm) and then transferred onto Hybond N-membranes (Amersham, Arlington Heights, IL). The treatment of the membranes, preparation of the probe, and the blot wash were the same as that described in the Genomic DNA southern blot section. The phage DNA, with human DNA insert, was purified by the Lambda TRAP Plus Kit (Clontech, Inc.) following the instructions of the manufacturer. The individual insert was released by restriction enzyme *Sst* I cleavage from the phage DNA arms, then subcloned into pUC118 plasmid.

**II.A.7. Northern analysis.** Two Human Multiple Tissue Northern Blot panels, MTN<sup>TM</sup>, and MTN<sup>TM</sup> II, were purchased from Clontech Inc. The MTN<sup>TM</sup> blot contains approximately 2  $\mu$ g of polyA<sup>+</sup> RNA per lane from eight different human tissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas). The MTN<sup>TM</sup> II blot contains the same amounts of mRNA from an additional eight different human tissues (spleen, thymus, prostate, testes, ovary, small intestine, colon, and peripheral blood leukocyte). The probe labeling and detection was the same as above.

**II.A.8. Human complimentary DNA (cDNA) library screening.** A human testes  $\lambda$ gt11 cDNA library (Human Testis cDNA library, Clontech, Inc.) was used to obtain an intact gene following the instructions of the manufacturer.  $2 \times 10^5$  plaques evenly distributed on 6 plates (150 X 15 mm) were transferred onto Hybond N-membranes. Southern analysis was performed as before. The phage DNA, with human cDNA insert, was purified by the  $\lambda$  Quick! Spin Kit (BIO 101, Inc.) following the instructions of the manufacturer. The individual insert was released by restriction enzyme *Eco* RI cleavage from the phage DNA arms, then subcloned into pUC118 plasmid.

**II.A.9. Reverse Transcription-PCR (RT-PCR).** Total RNAs were isolated from paired breast cancer and normal tissues by RNA isolation kit, RNA STAT-60 (TEL-TEST, Inc.). The first strand cDNA was synthesized by SuperScript Preamplification system kit (GIBCOBRL, Life Technologies). Oligomers E (ACCAGAGCGTCCAGTGTGTCC, sense) and F (TGGGACTTGATGATCTGAACC, antisense) were used to synthesize the *TSP50* gene. The predicted size was 699 bp.  $\beta$ -actin was used as an internal control whose sense and antisense primers were: 5'-GACGACATGGAGAAGATCTGG-3' and 5'-TGTAGAGGTAGTCAGTCAGG-3'. The predicted size for  $\beta$ -actin was 335 bp. The PCR reaction mixture consisted of cDNA derived from 125 ng of RNA, 10 pmole of sense and antisense primers from both *TSP50* and  $\beta$ -actin, 200  $\mu$ M of four deoxynucleotide triphosphate, and 0.125 unit of Taq DNA polymerase with reaction buffer (Perkin Elmer) in a final volume of 25  $\mu$ l. Thirty eight cycles of PCR were carried out. Each cycle of PCR included 30 seconds of denaturation at 95 °C, 60 seconds of annealing at 60 °C, and 60 seconds of extension at 72 °C. The PCR products were separated on a 2% agarose gel.

**II.A.10. *In situ* hybridization.** A 700 bp length of the 3' end anti-sense *TSP50* RNA, or its sense version which served as a negative control, was labeled with digoxigenin (Dig) and hybridized to properly treated breast cancer tissue sections embedded in paraffin. After incubation with anti-Dig-antibody conjugated biotin, the expression of *TSP50* in each tissue section was detected by streptavidin alkaline phosphatase and biotin complex (brown color). Hematoxylin was used for counterstaining (background stain, blue color). The colored signals were visible by light microscopy and the results were examined by two pathologists.

## II.B. Results

**III.B.1. Isolation of hypomethylated sequences from human breast cancer biopsies.** The DNAs isolated from five paired human breast cancer biopsies (tester) and their surrounding normal tissues (driver) were cleaved with the *Msp* I and *Mse* I enzymes. The tester and driver amplicons with both ends cleaved by *Msp* I were selectively prepared by PCR amplification (see Materials and Methods). After two rounds of DNA hybridization/subtraction and PCR amplification, individual fragments (DP2) were isolated from two breast cancer patients (see Materials and Methods). The DP2 fragments were subcloned into the pUC118 vector, and the inserts were amplified by PCR. 12 different sized inserts were selected from each MDD and used as probes for the master amplicon southern blotting. A total of four probes, *BR50*, *BR97*, *BR104*, and *BR254* were identified as candidates (Table 1).

Genomic Southern blot suggested that all four fragments were hypomethylated in the original patient, and also in some other breast and ovarian cancer patients. However, since *BR50* was located in the chromosome 3p12-14 region, whose abnormality was common in many different types of cancers, we decided to focus our attention on studying this fragment.

**II.B.2. Search for the coding regions by probe *BR50*.** Since *BR50* is a genomic fragment the chance that it encodes a polypeptide are slim because a majority of human genomic DNA

sequences are noncoding sequences. As a result, we decided that our first step in searching for a gene should be to isolate a longer DNA piece from a human genomic DNA library, with the hope that it may contain exon(s). It is an accepted fact that DNA methylation sites can be near genes (5), and with this in mind we decided to screen a human placenta genomic phage library, EMBL3 SP6/7 (Clontech, Inc.), where the insertion sizes were relatively small (9 to 28 kbp). For this purpose,  $2 \times 10^6$  plaques derived from the library were screened by probe *BR50*. As a result, a 17 kbp length clone was isolated. To obtain sequence information, the DNA clone was released from the phage DNA arms by restriction enzyme *Sst* I cleavage which generated eight DNA fragments. All eight fragments were subcloned into pUC118 plasmids. The fragments smaller than 1 kbp were completely sequenced, while the fragments larger than 1 kbp were partially sequenced from both the plasmid and insert junctions. A homolog search of the NIH GeneBank revealed two exons, *BR50-44* and *BR50-45*, which contained 112 and 132 nucleotides, respectively. Both exons encoded polypeptides which were about 50% identifiable to several mammalian proteases, such as serine proteases and tryptases. The *BR50-45* sequence was found 142 bps up stream of the *BR50* sequence.

Since we did not know the exact positions of the two exons in the 17 kbp fragment, it was possible that other exon(s) might lay between them. To gain a longer coding sequence, we designed four oligomers (A, B, C, D) based on both exon's sequence information to perform PCR. Oligomer A (5'-CCTGGATGGTCAGCGTG-3') and B (5'-CTGGGAGGCAATGATGGT-3'), which were on the complimentary strand, were based on the sequence information of *BR-44*; and C (5'-CTGGAGAGCCCTTGGTCT-3') and D (5'-CAGTGTGGTAGGAGGAG-3'), which were on the complimentary strand, were based on the sequence information of *BR-45*. A strategy using four different combinations of oligomer pairs was employed to perform PCR by utilizing the Human Universal cDNA Library Panel (Clontech Inc.). A PCR product which was about 700 bps in length was generated from one oligomer combination (A/D, 5'-CCTGGATGGTCAGCGTG-3'/5'-CAGTGTGGTAGGAGGAG-3'). This PCR product was directly sequenced. Combining the sequence information of the PCR product and the two exons, we obtained a cDNA fragment which contained 974 bps. A DNA homolog search of the NIH GeneBank revealed again, that it coded for a protease like protein, and the overall identity was approximately 40%.

**II.B.3. The candidate gene is highly, and specifically expressed in human testes.** To obtain a full length cDNA, it is critical to use the right cDNA library where the gene of interest is expressed. Thus, two Human Multiple Tissue Northern Blot panels, MTN<sup>TM</sup> and MTN<sup>TM</sup> II, containing 16 different tissue mRNAs (Clontech Inc.), were used to test the expression of the candidate gene by using the 700 bp cDNA PCR product as a probe. Our finding revealed that there were no visible transcripts of this gene in the eight mRNAs (heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas) included in the MTN<sup>TM</sup> panel (data not shown). However, in the MTN<sup>TM</sup> II panel, a 1.7 kb band was heavily hybridized by the probe exclusively in the testes mRNA as compared to the control probe, which was the human *rab6* gene (Fig. 1). These results suggested that the gene that we were searching for was a tissue specific gene. We have named the gene *TSP50* (Testes Specific Protease). At this moment, the gene's biological function(s) in human testes remain unknown.

**II.B.4. Isolation of the full length *TSP50* gene from a human testes cDNA library.** Since *TSP50* is highly expressed in human testes, to search for the full length *TSP50* gene, a human testes cDNA library (Human Testis cDNA library, Clontech, Inc.) was screened by the 700 bp *TSP50* cDNA sequence. A cDNA clone containing the probe sequence was isolated. Sequence analysis indicated that this fragment encoded a protein with 385 amino acids (Fig. 2.). There is a stop codon located at the 117th bp up stream of the initial translation site, and there is a 125 bp untranslated region before a polyadenosine sequence. These results implied that a full length gene thus had been obtained. It was also notable that the *BR50* probe sequence is located at the 3' end of the gene, and is only 17 bps down stream from the polyadenosine adding signaling site. The exons, *BR50-44* and *BR50-45*, encode amino acids from 103 to 157 and 308 to 385, respectively. The 3'- untranslated region before the polyadenosine site was also included in the sequence of *BR50-45*.

**II.B.5. DNA methylation status of the *TSP50* gene in human testes and other normal tissues.** Our studies have proven that *TSP50* is a tissue specific gene, and the methylation patterns in its 3'- region were altered in some breast and ovarian cancers. It is also common knowledge that many tissue specific genes are methylated, and this methylation may regulate their expression (6-8). To explore the possible relationship between *TSP50* gene expression and DNA methylation in different normal human tissues, southern analysis was performed. The normal tissues tested included the testes, where *TSP50* was expressed, and bladder, blood, breast, colon, lung, kidney, placenta, and ovary samples, where *TSP50* was apparently not expressed. To perform the southern analysis, *BR50* was used as a probe. DNAs isolated from the nine tissues were digested by *Msp* I, and *Hpa* II, which is an isoschizomer of the *Msp* I enzyme and the most popular enzyme used to study DNA methylation patterns (9). *Hpa* II digestion showed that in the testes DNA, two bands, probably released from each allele by enzyme cleavage, were hybridized by the probe. However, in the other tissues' DNAs, the corresponding bands were either not hybridized, or hybridized to a much smaller degree (Fig. 3a). For *Msp* I cleavage, both bands were released in different tissues to various extents (Fig. 3b). Both blots utilized a genomic fragment which did not detect differential DNA methylation as a control to determine complete enzymatic digestion (Fig. 3). These results demonstrated that the *TSP50* gene was differentially methylated in various human tissues. In general, DNA demethylation in the testes is correlated with high levels of gene expression. Conversely, DNA methylation is correlated with gene silencing in the bladder, blood, breast, colon, lung, kidney, placenta, and ovary tissues.

**II.B.6. Comparison of the *TSP50* product sequence with other serine proteases.** Sequence analysis revealed that the *TSP50* gene encodes a protein which shares approximately 40% identity with mammalian serine proteases. Figure 4 compares the *TSP50* amino acid sequence with 7 other serine proteases including prostaticin (10), plasma kallikrein (11), coagulation factor XI (12),  $\beta$ -tryptase (13), hepsin (14), plasminogen (15), and acrosin (16). Proteolytic enzymes dependent on a serine residue for catalytic activity are widespread and very numerous. Serine proteases are found in viruses, bacteria, and eukaryotes, and they include exopeptidases, endopeptidases, oligopeptidases, and omega peptidases. Over 20 families of serine peptidases are recognized (17,18), and grouped into clans that may have common ancestors. The peptidases of chymotrypsin, subtilisin, and carboxypeptidase C

clans have in common a "catalytic triad" of three amino acids: Serine (Ser, nucleophile). Aspartate (Asp, electrophile), and Histidine (His, base). However, there are some serine peptidases that have distinctive mechanisms of action without the classic Ser, His, Asp triad. The multiple sequence alignment for *tsp50p* showed that it contains triad His<sup>153</sup> and Asp<sup>206</sup>. However, the Ser at position 310 has been replaced by threonine (Thr) (Fig. 4). The corresponding nucleotides for coding Thr in the *TSP50* gene were ACT, while one base pair switch, such as C to G, will result in a Ser codon, AGT. As a result, one may wonder whether this change was caused by a point mutation happening in the cells, or an error in DNA sequencing. Based on our experience, these assumption are unlikely since the DNA fragment containing this codon was isolated from two individual libraries, the human placenta genomic phage library and testes cDNA library, and the ACT codon was verified by DNA sequencing in both fragments. This implies that the Ser was replaced by Thr in the predicted Ser triad of *tsp50p*. However, Thr and Ser residues are structurally similar (Thr has an extra methyl group as compared to Ser). Both Thr and Ser contain the HO group that is critical for enzymatic catalysis. In addition, the Thr residue in *tsp50p* was surrounded with conserved residues including a crucial glycine (Gly) (Fig. 4). Usually the linear order of catalytic-site residues, clusters of conserved amino acids around the catalytic residues, are important factors to classify a protease (17,18). Therefore, *tsp50p* could be a new type of serine protease, possibly with a distinctive mechanism of action.

**II.B.7. *TSP50* was differentially expressed in some breast cancer tissues.** Preliminary results demonstrated that *TSP50* was differentially methylated in 40% of the breast cancer tissues tested. This suggested that it could also be differentially expressed in breast cancer. To test this possibility, RT-PCR was carried out to determine *TSP50* expression levels in eighteen paired breast cancer tissues. Our findings showed that *TSP50* PCR products were generated in five tumor tissues, while in their normal controls, they were not visible relative to the control gene,  $\beta$ -actin (Fig. 5). Products generated from the five patients were gel purified and sequenced. DNA sequence analysis confirmed that the PCR products synthesized were the *TSP50* gene (data not shown). Therefore, among the eighteen paired samples tested, 28% of the tissues expressed the *TSP50* gene. At this moment, we can not answer the question of whether activation of the *TSP50* gene in cancer is a consequence, or a causal factor of neoplastic growth. To find the truth, it will be necessary to perform in vitro cellular transformation and in vivo tumor induction assays.

**II.B.8. *In situ* hybridization confirmed that *TSP50* was expressed in breast cancer cells.** Although RT-PCR detected *TSP50* gene activation in some breast cancer biopsies, this experiment did not clarify whether this gene was expressed in the cancer or stroma cells. To find the answer, *In Situ* Hybridization (ISH) assay was performed, where an anti-sense probe was used to detect the *TSP50* gene expression in breast cancer tissue sections. At this point, three breast cancer and one benign tumor have been tested. The results found that the anti-sense probe detected *TSP50* transcripts (brown color) in cancer cells of an advanced cancer specimen. Some of the cancer cells (epithelia cells) were stained heavily (darker brown) (Fig. 10a) in comparison to other cancer cells (lighter brown) (Fig. 10b). The reaction product in the adjacent extracellular matrix (Fig. 10a and b) is likely to be due to the binding of brown oxidized diaminobenzide, which has diffused from the original intracellular site of reaction. In the negative controls, the anti-sense and sense probe did not stain normal or

cancer breast epithelia cells (Fig. 10C and Fig. 10D). Therefore, they only exhibit counterstaining (blue). The other two breast cancer and benign samples were not stained by the anti-sense probes. (Data not shown). These results demonstrated that the *TSP50* gene was activated in some breast cancer cells, which indicated that this gene could be involved in neoplastic evolution, and perhaps metastatic progression.

### III. Key Research Accomplishments

The key research accomplishments of our study are:

- 1). The establishment of a new technique, MDD;
- 2). The successful generation of DMGFs by MDD, which will be useful tools for new breast cancer related genes;
- 3). The acquisition of a novel gene, *TSP50*;
- 4). The discovery of abnormal activation of *TSP50* in breast cancer;
- 5). The determination of abnormal activation of *TSP50* in epithelia breast cancer cells.

### IV. Reportable Outcomes

- 1). The studies on obtaining and characterizing the *TSP50* gene have been published in the *Cancer Research* journal (see appendix).
- 2). An abstract was presented about *TSP50* at the 2000 AACR meeting.
- 3). A pending patent has been filed for the *TSP50* gene.
- 4). Established cell lines that integrated the *TSP50* gene into their genomes.
- 5). NIH funding was applied for based on the *TSP50* gene study.
- 6). The postdoctoral fellow who worked on the proposal was trained by this award.

### VI. Conclusions

The important and unique feature of the new Methyl-Differential Display technique is to selectively analyze CG rich, differentially methylated sequences, which are usually close to coding regions, by *Msp* I and partner enzyme cleavage. To date four DMGFs, which detected DNA hypomethylation, were isolated from breast cancer patients. Among them three also detected DNA hypomethylation in ovarian cancer samples (Table 1). All the DMGFs had high GC contents, and one DMGF, *BR50*, was successfully used as a probe to discover the coding region which was only 140 bps away. These regions' sequencing information led to the discovery of a 974 bp gene fragment from a human cDNA library panel by PCR amplification. To obtain a full length gene, a northern evaluation of sixteen different types of human RNAs was performed. The results demonstrated that the target gene was specifically expressed in human testes tissue. This information secured the isolation of an intact gene, *TSP50*, by screening a human testes cDNA library. The sequence analysis revealed that the *TSP50* gene most likely encodes a serine protease.

It is well known that proteases of all major classes (i.e., serine, aspartic, cysteine,

threonine, and metalloproteinases) are linked with various malignancies, especially those exhibiting the metastasis phenotype. For example, the prostate specific antigen (PSA) is a kallikrein-like serine protease that is utilized as a clinical marker for the diagnosis and staging of prostate cancer where its preferential expression in prostate epithelial cells is increased (15-20). In addition, the matrix metalloproteinases (MMPs) have been repeatedly implicated in metastasis (21-23). Since the *TSP50* gene product (*tsp50p*) could be a serine protease, and was activated in breast cancer cells, it is logical to proceed to the next step and ask whether this gene could play a role in breast cancer invasiveness?

It is common knowledge that many tissue specific genes' expression is regulated by DNA methylation which usually modifies the promoter, or sometimes the 3'- regions (2-4, 24). Our preliminary results, although only obtained from analyzing the DNA methylation status of the 3' flanking region of the gene, have proven that *TSP50* is one of those tissue specific genes. It will be interesting to discover whether the gene's promoter region is also methylated when the corresponding sequence information is available. The *Hpa* II and *Msp* I methylation sensitive southern analysis of the *TSP50* gene's 3'- region demonstrated that, in *Hpa* II digested DNAs, probe *BR50* hybridized two bands in the testes tissue, but none in the other samples. The lower band, which was the same size as the probe, represented the unmethylated DNA pattern, while the upper band obviously contained the internal *Hpa* II recognition site(s) which remained methylated. In *Msp* I digested DNAs, the upper band was dominant in most tissues, while in the testes, the lower band was dominant. These results suggest that the GGCCGG end of *BR50* was methylated in other tissues, but not in the testes. The DNA methylation patterns observed in both blots are probably allelic oriented. It seems that DNA hypomethylation was accompanied by the gene's expression in the testes, and conversely, DNA hypermethylation was accompanied by the gene's silencing in other tissues. The correlation between DNA methylation and gene expression provided additional proof that DNA methylation could be an important mechanism in governing the genes' expression in various differentiated human cells.

The differential expression of the *TSP50* gene has been tested in eighteen paired breast cancer biopsies. Our findings have shown that this gene was activated in five cancer samples. This finding indicates that this novel gene's expression is related to breast cancer progression. In addition, in situ hybridization has demonstrated that the gene was activated in the epithelia cancer cells. We believe that the cellular location of the *TSP50* gene product will soon be uncovered since the antibody for TSP50 is now available. By performing the immunohistochemistry technique, the statistic data for activation of this new gene in breast cancer, as well as other cancers will be obtained. This information will help us to understand whether the *TSP50* gene can be considered as a bio-marker for diagnosis or prognosis of human breast cancer.

## VII. References

1. Sambrook, J., Fritsch, E. F. and Manitis, T. in *Molecular Cloning Manual*, 2nd ed. (ed. Ford, N. Nolan, C. and Ferguson, M.) 9.16-9.19 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989).

2. Yuan, L. M., Shan, J. D., De Risi, D., Broome, J., Lovecchio, J., Gal, D., Vinciguerra, V., and Xu, H. P., 1999. Isolation of a novel gene, *TSP50*, by a hypomethylated DNA fragment in human breast cancer. *Cancer Res.*, 59, 3215-3221.
3. Lisitsyn, N., Lisitsyn, N. and Wigler, M. Cloning the differences between two complex genomes. *Science* 259: 946-951, 1993.
4. Walter, M. A., Spillet, D. J., Thomas, P., Weissenbach, J., and Goodfellow, P. N., A method for constructing radiation hybrid maps of whole genomes. *Nature Genet.* 7: 2-28, 1994.
5. Larsen, F., Gunderson, G., Lopez, R., and Prydz, H. CpG islands as gene markers in the human genome. *Genomics*, 13: 1095-1107, 1992.
6. Bird, A. Gene number, noise reduction and biological complexity. *Trends Genet.*, 11: 94-100, 1995.
7. Kass, S. U., Pruss, D., and Wolffe, A. P. How does DNA methylation repress transcription? *Trends Genet.*, 13: 444-449, 1997.
8. Siegfried, Z., and Cedar, H. DNA methylation: a molecular lock. *Curr. Biol.*, 7: R305-R307, 1997.
9. Nelson, M., and McClelland, M. Site-specific methylation: effect on DNA methylation methyltransferases and restriction endonucleases. *Nucl. Acids Res.*, 19: 2045-2071, 1991.
10. Yu, J. X., Chao, L., and Chao, J., 1995. Molecular cloning, tissue-specific expression, and cellular location of human prostaticin mRNA. *J. Biol. Chem.* 270, 13483-13489.
11. Chung, D. W., Fujikawa, K., McMullen, B. A., and Davie, E. W., 1986. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. *Biochemistry* 25, 2410-2417.
12. Fujikawa, K., Chung, D. W., Hendrickson, L. E., and Davie, E. W., 1986. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. *Biochemistry* 25, 2417-2424.
13. Vanderslice, P., Ballinger, S. M., Tam, E. K., Goldstein, S. M., Craik, C. S., and Caughey, G. H., 1990. Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. *Proc. Natl. Acad. Sci. U. S. A.* 87, 3811-3815.
14. Leytus, S. P., Loeb, K. R., Hagen, F. S., Kurachi, K., and Davie, E. W., 1988. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. *Biochemistry* 27, 1067-1074.
15. Forsgren, M., Raden, B., Israelsson, M., Larsson, K., and Heden, L.-O., 1987. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. *FEBS Lett.* 213, 254-260.
16. Adham, I. M., Klemm, U., Maier, W.-M., and Engel, W., 1990. Molecular cloning of human preproacrosin cDNA. *Hum. Genet.* 84, 125-128.
17. Barrett, A. J., 1994. Classification of peptidases. *Methods in Enzymol.* 244, 1-14.
18. Rawlings, N. D., and Barrett, A. J., 1994. Families of serine peptidases. *Meth. Enzymol.* 244, 19-31.
19. Wang, M. C., Valenzuela, L.A., Murphy, G. P., and Chu, T. M., 1979. Purification of a human prostate specific antigen. *Invest. Urol.* 17, 159-163.
20. Yoshihito, B., Wang, M. C., Watt, K. W. K., Loo, R., and Chu, T. M., 1984. The proteolytic activity of human prostate-specific antigen. *Bioch. & Biophys. Res. Commun.* 123, 482-488.


21. Chambers, A. F., and Matrisian, L. M., 1997. Changing views of the role of matrix metalloproteinases in metastasis. *J. Natl Cancer Inst.* 89, 1260-1270.
22. Powell W. C., and Matrisian, L. M., 1996. Complex roles of matrix metalloproteinases in tumor progression. In: Gunthert U. Birchmeier W. Editors. Attempts to understand metastasis formation I: metastasis-related molecules. Berlin: Springer-Verlag, p1-21.
23. Birkedal-Hansen, H., Moore, W. G., Bodden, M. K., Windsor, L. J., Birkedal-Hansen, B., DeCarlo, A., et al., 1993. Matrix metalloproteinases: a review. *Crit. Rev. Oral Biol. Med.* 4, 197-250.
24. Graff, J. R., Herman, J. G., Myohanen, S., Baylin, S. B., and Vertino, P. M. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in *de novo* methylation. *J. Biol. Chem.*, 272, 22322-22329, 1997.

### VIII. Table and Figures

Table 1. The Characters of the DMGFs isolated by MDD

NAME	CHROM	ABNORMALITY	GENOMIC/SEQ (bps)	cDNA/SEQ (bps)	PROTEIN
BR50	3p12-14	HypoM in BR/OV*	1005	244	Proteinase
BR97	12q24	HypoM in BR/OV	693		
BR104	19	HypoM in BR	307		
BR254	8q11-12	HypoM in BR/OV	332		

\* Breast (BR) and Ovarian (OV) cancer.



**Fig. 1.** Northern blot results analyzed by a fragment of the *TSP50* gene. The Human Multiple Tissue Northern Blot panel, MTN<sup>TM</sup> II, containing 8 different tissues' mRNA (Clontech Inc.) was tested to determine the expression levels of the gene. Compared to the control, the human Rab6 gene, which was evenly expressed in all tissues, *TSP50* was highly expressed in the testes tissue, but not in the others. No single tissue (total eight) in another Human Multiple Tissue Northern Blot panel was hybridized with the probe (data not shown).

-59 gtcgtgggggcggc  
actgggagcgccttccggagagacgcagtcgggctgccaccccggg

1 **at**gggtcgctggtgccagaccgctcgcgcgcgggcagcgcccccg  
M G R W C Q T V A R G Q R P R  
46 acgtctgccccctcccgcgcccgtgcctgctgctgctgcttctg  
T S A P S R A G A L L L L L L  
91 ttgctgaggtctgcaggttgcggggcgaggggaagccccggg  
L L R S A G C W G A G E A P G  
136 gcgctgtccactgctgatcccgccgaccagagcgtccagtgtgtc  
A L S T A D P A D Q S V Q C V  
181 cccaaggccacctgtccttccagccggcctcgccttctctggcag  
P K A T C P S S R P R L L W Q  
226 accccgaccaccagacactgccctcgaccaccatggagacccaa  
T P T T Q T L P S T T M E T Q  
271 ttcccagtttctgaaggcaaagtcgaccataaccgctcctgtggc  
F P V S E G K V D P Y R S C G  
316 ttttctacgagcaggacccccaccctcagggacccagaagccgtg  
F S Y E Q D P T L R D P E A V  
361 gctcggcgggtggccctggatggtcagcgtgcgggccaatggcaca  
A R R W P W M V S V R A N G T  
406 cacatctgtgccggcaccatcattgcctcccagtggtgctgact  
H I C A G T I I A S Q W V L T

451 *gtggcccaactgcctgatctggcgtgatgttatctactcagtgagg*  
 V A H C L I W R D V I Y S V R  
 496 *gtggggagtgccgtggattgaccagatgacgcagaccgcctccgat*  
 V G S P W I D Q M T Q T A S D  
 541 *gtccccggtgctccaggtcatcatgcatagcaggtaccgggcccag*  
 V P V L Q V I M H S R Y R A Q  
 586 *cggttctggctcctgggtgggccaggccaacgacatcggcctcctc*  
 R F W S W V G Q A N D I G L L  
 631 *aagctcaagcaggaactcaagtacagcaattacgtgcggcccatc*  
 K L K Q E L K Y S N Y V R P I  
 676 *tgcctgcctggcacggactatgtggtgaaggaccattcccgtctgc*  
 C L P G T D Y V L K D H S R C  
 721 *actgtgacgggctggggactttccaaggctgacggcatgtggcct*  
 T V T G W G L S K A D G M W P  
 766 *cagttccggaccattcaggagaaggaagtcatcatcctgaacaac*  
 Q F R T I Q E K E V I I L N N  
 811 *aaagagtgtgacaatttctaccacaacttcaccaaatacccact*  
 K E C D N F Y H N F T K I P T  
 856 *ctggttcagatcatcaagtcccagatgatgtgtgcgaggacacc*  
 L V Q I I K S Q M M C A E D T  
 901 *cacagggagaagttctgctatgagctaactggagagcccttggtc*  
 H R E K F C Y E L T G E P L V  
 946 *tgctccatggagggcacgtggtacctggtgggattggtgagctgg*  
 C S M E G T W Y L V G L V S W  
 991 *ggtgcaggctgccagaagagcgaggccccacccatctacctacag*  
 G A G C Q K S E A P P I Y L Q  
 1036 *gtctcctcctaccaacactggatctgggactgcctcaacgggcag*  
 V S S Y Q H W I W D C L N G Q  
 1081 *gccctggccctgccagccccatccaggaccctgctcctggcactc*  
 A L A L P A P S R T L L L A L  
 1126 *ccactgcccctcagcctccttgctgccctctgactctgtgtgccc*  
 P L P L S L L A A L \*  
 1171 *tccctcacttg*

**Fig. 2.** The nuclear acid and amino acid sequence of TSP50.

```

TSP50:          TLRDPEAVAR RWPWVSVRA ....WGTHI CAGHIIASQW VLTVAHCLIW RDVIYSVRVG
Prostasin:     ITGCSSAVAG QWPWQVSLTY ..EG...VHV CCGSLVSEQW VLTAAHCFPS EHKKEAYEVK
Plasma kallikrein: IVGGTNSSWG EWPWQVSLQV ..KLTAQRHL CCGSLIGHQW VLTAAHCFDG LPLQDVWRIY
Coagulation factor XI: IVGG...V... IWPWQV...L... CCGS...W... VLTAAH...V...
β-Trypsin:     IVGGQEAPRS KWPWQVSLRV ..HGPIYMHF CCGSLIHPQW VLTAAHCVGP D.VKDLAALR
Hepsin:        IVGGADTSLG RWPWQVSLRY ....D.GAHL CCGSLVSGDW VLTAAHCFPE RRVVLSNRV
Plasminogen:   IVGCVVAHPH SWPWQVSLRT ....RFGMHF CCGSLISPEW VLTAAHCLLE KSPRPSSYKV
Acrosin:       IVGCAAQHG AWPWVSLQI FTYNSHRYHT CCGSLNSRW VLTAAHCFVG KNNVHDNRIV
                ▲


SPWIDQMTQT ASDVPVLQVI MHSRYRAQRF WSW..... VGQANDIGLL KLRQELKYSN YVRPICLPGT DYVLKDHSR.
LGAH.....Q LDSYSEDAKV STLRDIIPHP SYLQ..... EGSOQDIALI QLSRPIFFSR YIRPICLPAA NASFPNG.LH
SGIL.....N LSDITKDTPF SQIKETIIEHQ NYKV..... SEGNHDIALI KLQAPLNYTE FQKPICLPSPK GDTSTIY.TN
VQLR....E QHLYYQDQLL P.VSRIIVHP QFYT..... AQIGADIALI ELEEPVKVSS HVHTVILPPA SETFPFG.MP
FA.....GA VAQASPHGLQ LGVQAVVYH GYLPIRDPNS EERSEDIALL HESSPIPLTE YIQPVCCLPA GQALV.DGKT
IL.....GA HQEV...NLE PHVQIEVSR LFL..... EPTRKDIALI KLSSPAVITD KVTPACLSP NYVVA.DRTE
FGAKETTYGN NKPVKAPVQF RYVEKIIIEH KY.....NS ATEGNDIALV EITPPIISGR FICPGCLPHI KAGLPRGSQS
                ▲

CIVTGWGLSK ADGMWPQFRT IQEKEVIILN NKECDNFYHN FTKIPTLVQI IKSQMCAGE DTHREKFCYE LTGEPLVCSM
CIVTGWGHVA PSVSLLPKP LQOLEVPLIS RETCNCLYNI DA.KPEEPHF VQEDMVCAGY VEGGKDACG DSGGPLSCPV
CIVTGWGFSK EKGEI..QNI LQKVNIPLVT NEECQKRYQ. ....DYK ITQRMVCAGY KEGGKDACG DSGGPLVCKH
CIVTGWG... L... L... N... C... F... M... CAGY... G... D... C... G... DSGGPL...C
CIVTGWGDVD NDERLPPFPF LKQVKVPIME NHICDAKYHL GAYTGDDVRI VRDDMLCAGY .NTRRDSQCG DSGGPLVCKV
CIVTGWGHIQ .YYG.QQAGV LDFARVPHIS NQVCRQADPY GN.....O IKPKMVCAGY PEGGKDACG DSGGPLVCKD
CIVTGWGETQ GTFG...AGL LKEAQLPVIE NKVCNRYEFL NG.....R VQSTELCAGH LAGGTDSCG DSGGPLVCFE
CIVTGWGYIE EKAP.RPSSI LMEARVDLID LDLCNSTQWY NG.....R VQPTNV CAGY PVGKIDICG DSGGPLVCKD
                ▲


....EGTWYL VGLVSWGAGC QKSEAPPYIL QVSSYQHNIW DCLNGQALAL PAPSRTILLA .....
....EGLWYL TGVSWGAC GARNRPGVYT LASSVSNIG SKVTELQPRV VPQTQESQPD .....
....NGMWRD VGITSWGAGC ARRECPGVYT KVABYMDWIL EKTQSSDGKA QMQSPA
....R...W...L... V...S...W...G...C...A...I...P...G...Y...T...N...V...Y...W...I...E...L...Y...
....NGTWLQ AGVSWGEGC AOPNRPGYT RVTYLDWIH HYVPKPP
SISRTPHWL QGVSWGIGC AIAORPGVYT KVSDFRWIL QAKTSEKAS GMVTQI
....KDKYIL QGVSWGIGC ARPNKPGVYT RVSREVTWIE GVMRNN
..SKFSAYVV VGITSWGAGC AKARNPGVYT ATWPLNWLIA SKIGSNALRM IQSATPPPPT .....

```

**Fig. 3.** Comparison of the deduced *TSP50* amino acid sequence with other serine proteases. The amino acid sequences of these serine proteases correspond to the mature form of  $\beta$ -trypsin or the catalytic chains of acrosin, prostasin, plasma kallikrein, coagulation factor XI, serine protease hepsin, and plasminogen. Amino acid residues that are highly conserved are shaded, and the catalytic triad of histidine, aspartic acid, and serine are indicated by triangles. Dots represent gaps to bring the sequences to better alignment.




**Fig. 4.** DNA methylation status of the *TSP50* gene in nine normal human tissues examined by southern blot. In a and b, the results obtained from *Hpa* II and *Msp* I digestion, respectively. 6 µg of DNA isolated from each tissue were cleaved by the enzymes and subjected to southern analysis by probe *BR50*. a. The results show that bands which are approximately 1 kbp and 2 kbp in length were released by *Hpa* II only in the testes tissue. b. A 2 kbp band was released by *Msp* I in most tissues. In a and b. The control probe hybridizes a single band in each tissue's DNA, which provides proof of complete enzymatic digestion.



**Fig. 5.** The results of RT-PCR for differential expression of *TSP50* in five out of eighteen breast cancer and normal control tissues tested. Lane MW represents *Hae* III ø174 markers in base pairs. The *β-actin* and *TSP50* lanes served as positive controls, and were generated by using cDNA prepared from testes tissue RNA. Lane *β-actin*+*TSP50* contains simultaneously generated *TSP50* and *β-actin* from testes cDNA. The number for each patient tested is listed above the bracket. T and N represent tumor and normal tissues. The result shows that the *TSP50* gene was

abnormally activated in approximately 30% of breast cancer patients.



**Fig. 6.** The results of *In Situ* Hybridization of an advanced cancer specimen. In a, the anti-sense probe detected *TSP50* transcripts stained with a darker brown color pointed out by arrows. In b, the anti-sense probe detected *TSP50* transcripts stained with a lighter brown color pointed out by arrows. In c. The anti-sense probe did not stain normal breast tissue (negative control). In d. the sense probe did not cause any brown color staining (negative control), the blue staining represents the counterstaining by hematoxylin. Magnification 150 X.

### VIII. Appendices

- 1). A reprint of the article which was published in the *Cancer Research Journal*.
- 2). The AACR annual meeting abstract.
- 3). A copy of the patent application.
- 4). A curriculum vitae of the PI.
- 5). A list of personnel receiving pay from the research effort.

# Isolation of a Novel Gene, *TSP50*, by a Hypomethylated DNA Fragment in Human Breast Cancer<sup>1</sup>

Liming Yuan, Jidong Shan, Dwight De Risi, John Broome, John Lovecchio, David Gal, Vincent Vinciguerra, and Hao-peng Xu<sup>2</sup>

Molecular Oncology, Hematology/Oncology Medicine [L. Y., J. S., V. V., H-p. X.], Department of Surgery [D. D. R.], Department of Laboratories [J. B.], and Division of Gynecologic Oncology [J. L., D. G.], North Shore-Long Island Jewish Health System, New York University School of Medicine, Manhasset, New York 11030

## ABSTRACT

A novel gene, testes-specific protease 50 (*TSP50*), was isolated from a human testes cDNA library by using a genomic DNA probe, *BR50*. *BR50* was isolated by a modified representational difference analysis (RDA) technique due to its hypomethylated feature in a breast cancer biopsy. This altered DNA methylation status was also detected by *BR50* in other breast and some ovarian cancer tissues. The *TSP50* gene product is a homologue to several human proteases, which indicates that it may encode a protease-like protein. Northern analysis of 16 different types of normal human tissues suggests that *TSP50* was highly and specifically expressed in human testes, which indicates that it might possess a unique biological function(s) in that organ. Methylation status analysis in normal human testes and other tissues showed a correlation between DNA methylation and gene expression. Most importantly, reverse transcription-PCR analysis of 18 paired breast cancer tissues found that in 28% of the cancer samples, the *TSP50* gene was differentially expressed. The possibility that *TSP50* may be an oncogene is presently under investigation.

## INTRODUCTION

Abnormal DNA methylations (hypomethylation or hypermethylation) have been linked to various human diseases including cancers (1-8). Because methylated DNA sites are usually close to genes (9-13), searching for differentially methylated DNA fragments in cancer could pinpoint genes of interest. Consequently, a modified RDA technique using human breast cancer biopsies as starting material was used to search for differentially methylated DNA fragments. Unlike traditional RDA<sup>3</sup> (14), to perform modified RDA, the restriction enzyme *MspI*, which is sensitive to the methylated GC-rich sequence GGC<sup>m</sup>CGG (15-18), was used as a master enzyme to cleave genomic DNAs for amplicon preparation. *MspI* is a relatively frequent cutting enzyme (19), which, when used alone, produces an amplicon of high complexity that can cause unsuccessful subtractive hybridization. Hence, a second restriction enzyme, or "partner enzyme," has been incorporated into the technique. The amplicons can only be made by PCR from DNA fragments with both ends cut by the *MspI* enzyme.

As a result of using this modified technique, two DNA fragments, *BR50* and *BR254*, were isolated that detected DNA hypomethylation in breast cancer. Additional studies verified that both fragments also detected hypomethylation in ovarian cancer, and *BR254* was amplified in 1 of 10 breast cancer biopsies. On the basis of these findings, we considered both fragments good candidates to search for genes that might be related to various malignancies. This report will focus on presenting the detailed studies related to *BR50*, which covers its own

isolation as a differentially methylated DNA fragment, to its utilization in the discovery of a novel gene, *TSP50*.

Investigation of the *TSP50* gene has found that it encodes a protease-like protein. Northern analysis of multiple human tissue RNA expression panels showed that *TSP50* is a tissue-specific gene, which was heavily expressed in human testes. There were almost no visible amounts of *TSP50* transcript displayed in the other 15 types of human tissues in the panels. This result indicates that the *TSP50* gene holds a special physiological function(s) in human testes. The DNA methylation status of the downstream region of the gene in normal human testes and eight other tissues was also examined. Apparently, DNA methylation silences the *TSP50* gene expression in those eight normal tissues, whereas DNA demethylation in human testes could be a key element responsible for gene expression. Furthermore, RT-PCR was performed to examine differential expression in breast cancer and matched normal control tissues. We found that ~28% of the cancer samples tested expressed the *TSP50* gene, whereas the corresponding controls did not. Whether there is a relationship between gene expression and cancer development is presently under investigation.

## MATERIALS AND METHODS

**DNA from Human Cancer Biopsies.** Dissected human breast and ovarian cancer tissues (tumor and matched normal) were immediately frozen in liquid nitrogen and stored at -70°C. DNAs were isolated from those tissues by the phenol extraction method (20).

**Modified RDA.** One to two µg of DNA (tester) isolated from human breast cancer biopsies and their matched normal DNA (driver) were cleaved with *MspI* (20 units/µl; Boehringer Mannheim) and *MseI* (20 units/µl; New England Biolabs, Inc.) in a 50-µl reaction for 3 h. To prepare tester and driver master amplicons, the *MspI*- and *MseI*-digested tester and driver genomic DNAs were ligated to 1.5 µg of MSA24-mer and 0.75 µg of MSA12-mer (Table 1); these were the first pair of oligonucleotide linkers that only recognize the ends generated by *MspI*. The procedures for amplicon preparation were performed as described (14). The DNA amplicons were then purified by phenol, phenol/chloroform extraction. To remove the first set of linkers from the driver amplicon, 80 µg of driver amplicon DNA were digested with the *MspI* enzyme (10 units/µl). To change the tester master amplicon DNA linkers, 5 µg of tester master amplicon were digested with *MspI* (20 units/µl) and ligated to 0.6 µg of MSB24-mer and 0.3 µg of MSB12-mer (Table 1); these were the second set of oligonucleotide linkers. Subtractive hybridization was performed as described (14). The first round of difference products (DP1) were amplified as described (14). To prepare the second round of subtractive hybridization, 3 µg of DP1 were digested with the restriction endonuclease *MspI* (20 units/µl). To put a new set of linkers on DP1, 0.1 µg of DP1 was mixed with 0.6 µg of MSC24-mer and 0.3 µg of MSC12-mer (Table 1). Another round of subtractive hybridization/PCR amplification was repeated. The second round of difference products (DP2) usually contained several individual DNA fragments when electrophoresed on a 2% agarose gel. The individual DNA fragments were purified by DNA gel extraction kit (Qiagen, Inc.) and subcloned into pUC118 vector, which was linearized by the restriction endonuclease *AccI* and transformed into *Escherichia coli* (*DH5α*). Twelve cloned inserts were chosen to be amplified, from which different-sized probes were selected for master amplicon Southern blot. The candidate probes were then further tested by human genomic DNA Southern blot.

**Amplicon DNA Southern Blot.** The first round of positive probe screening was performed with amplicon DNA Southern blots. Non-Radiation South-

Received 10/28/98; accepted 5/3/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Supported by Grant DAMD17-97-7070 from the Department of Defense Breast Cancer Research Program, Cancer Research Grant 09289 from North Shore-Long Island Jewish Health System, and the Greenberg Foundation.

<sup>2</sup> To whom requests for reprints should be addressed, at Molecular Oncology, Research Building, North Shore-Long Island Jewish Health System, 350 Community Drive, Manhasset, NY 11030.

<sup>3</sup> The abbreviations used are: RDA, representational difference analysis; RT-PCR, reverse transcription-PCR; DP, difference product; TSP, testes-specific protease.

Table 1 Sequence of the oligonucleotides for PCR amplification

Primer	Sequence
MSA24	5'-CTCGTCGTCAGGTGCTGCTTAC-3'
MSA12	5'-CGGTGAAGCACT-3'
MSB24	5'-TAGAGCCACGTAGCTGCTGTAGTC-3'
MSB12	5'-CGGACTACAGCA-3'
MSC24	5'-ACCGTGGACTGGATAGGTTTCAGAC-3'
MSC12	5'-CGGTCTGAACCT-3'

ern Blot and Detection kits (Genius) were purchased from Boehringer Mannheim. Probe labeling and detection followed the instructions of the manufacturer. Two to three  $\mu\text{g}$  of tester and driver amplicon DNA were electrophoresed on a 2% agarose gel and blotted to positively charged nylon membranes (Boehringer Mannheim). For prehybridization, the membranes were placed at 68°C for 2–4 h in solutions containing 6 $\times$  SSC, 5 $\times$  Denhardt's solution, 0.5% SDS, 0.1 M EDTA, and 50  $\mu\text{g}/\text{ml}$  of salmon sperm DNA. Under the same conditions, the probes were added and hybridized to the membranes overnight. The membranes were then rinsed three times with 2 $\times$  SSC, 1 $\times$  Blot wash (12 mM Na<sub>2</sub>HPO<sub>4</sub>, 8 mM NaH<sub>2</sub>PO<sub>4</sub>, 1.4 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>, and 0.5% SDS) at 68°C and further washed three times (30 min each) with the same buffer at 68°C. Next, the membranes were equilibrated in buffer A (100 mM Tris-HCl, 150 mM, pH 7.5) and transferred into buffer B (2% block reagent in buffer A), which was incubated at room temperature for 1 h. The membranes were then washed 2 times for 15 min with buffer A and equilibrated in buffer C (100 mM Tris-HCl, 100 mM NaCl, and 10 mM MgCl<sub>2</sub>). Before the membranes were exposed on Kodak X-OMAT film for 1 h, they were rinsed in lumi-P530 for 1 min and kept in a plastic sheet protector.

**Genomic DNA Southern Blot.** Genomic DNAs were digested with a desired restriction enzyme (20 units/ $\mu\text{l}$ ) and electrophoresed on 1.5% agarose gels, which were then transferred to Hybond N<sup>+</sup> membranes (Amersham). These membranes were exposed to UV light to immobilize the DNA. Probes for the Southern blot were labeled with High Prime DNA labeling kits (Boehringer Mannheim) following the instructions of the manufacturer. The procedure for hybridization and blot wash were the same as in the Amplicon DNA Southern blot section.

**Northern Analysis.** Two Human Multiple Tissue Northern blot panels, MTN and MTN II, were purchased from Clontech, Inc. The MTN blot contains ~2  $\mu\text{g}$  of poly(A)<sup>+</sup> RNA per lane from eight different human tissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas). The MTN II blot contains the same amounts of mRNA from an additional eight different human tissues (spleen, thymus, prostate, testes, ovary, small intestine, colon, and peripheral blood leukocyte). The labeling and detection of the probes were the same as above.

**DNA Sequence and Chromosome Assignment.** The pUC118 plasmid containing the candidate DNA fragment was sequenced using the Ampli-Cycle sequencing kit (Perkin-Elmer), under conditions described by the manufacturer. Chromosome assignment for the candidate DNA fragment was determined by genomic Southern blot of the *Hind*III digested monochromosomal human/rodent somatic cell hybrid mapping panel #2 (NIGMS Human Genetic Mutant Cell Repository) while it was used as a probe. Fine chromosome mapping was performed with GeneBridge 4 Radiation Hybrid Panel (Research Genetics, Inc.) by PCR amplification (21).

**Human Genomic DNA Library Screening.** A human placenta genomic phage library, EMBL3 SP6/T7 (Clontech, Inc.), was used for cloning a longer genomic fragment containing the candidate fragment. Phage infection procedure was based on the instructions supplied by the manufacturer. Plaques (2  $\times$  10<sup>6</sup>) were evenly distributed on 20 plates (150  $\times$  15 mm), then transferred onto Hybond N<sup>+</sup> membranes. The treatment of the membranes, preparation of the probe, and the blot wash were the same as that described in the Genomic DNA Southern blot section. The phage DNA, with human DNA insert, was purified by the Lambda TRAP Plus kit (Clontech, Inc.) following the instructions of the manufacturer. The individual insert was released by restriction enzyme *Sst*I cleavage from the phage DNA arms, then subcloned into pUC118 plasmid.

**Human cDNA Library Screening.** A human testes  $\lambda\text{gt}11$  cDNA library (Human Testes cDNA Library; Clontech, Inc.) was used to obtain an intact gene following the instructions of the manufacturer. Plaques (2  $\times$  10<sup>5</sup>) evenly distributed on six plates (150  $\times$  15 mm) were transferred onto Hybond N<sup>+</sup>

membranes. Southern analysis was performed as before. The phage DNA, with human cDNA insert, was purified by the  $\lambda$  Quick! Spin kit (BIO 101, Inc.) following the instructions of the manufacturer. The individual insert was released by restriction enzyme *Eco*RI cleavage from the phage DNA arms, then subcloned into pUC118 plasmid.

**RT-PCR.** Total RNAs were isolated from paired breast cancer and normal tissues by RNA isolation kit, RNA STAT-60 (TEL-TEST, Inc.). The first-strand cDNA was synthesized by SuperScript Preamplification system kit (Life Technologies, Inc.). Oligomers E (ACCAGAGCGTCCAGTGTGTCC, sense) and F (TGGGACTTGATGATCTGAACC, antisense) were used to synthesize the *TSP50* gene. The predicted size was 699 bp.  $\beta$ -actin was used as an internal control, the sense and antisense primers of which were 5'-GACGACATG-GAGAAGATCTGG-3' and 5'-TGTAGAGGTAGTCAGTCAGG-3'. The predicted size for  $\beta$ -actin was 335 bp. The PCR reaction mixture was comprised of cDNA derived from 125 ng of RNA, 10 pmol of sense and antisense primers from both *TSP50* and  $\beta$ -actin, 200  $\mu\text{M}$  of four deoxynucleotide triphosphate, and 0.125 unit of *Taq* DNA polymerase with reaction buffer (Perkin-Elmer) in a final volume of 25  $\mu\text{l}$ . Thirty-eight cycles of PCR were carried out. Each cycle of PCR included 30 s of denaturation at 95°C, 60 s of annealing at 60°C, and 60 s of extension at 72°C. The PCR products were separated on a 2% agarose gel.

## RESULTS

**Isolation of Hypomethylated Sequences from Human Breast Cancer Biopsies.** The DNAs isolated from three paired human breast cancer biopsies (tester) and surrounding normal tissues (driver) were cleaved with the *Msp*I and *Mse*I enzymes. The tester and driver amplicons with both ends cleaved by *Msp*I were selectively prepared by PCR amplification (see "Materials and Methods"). After two rounds of DNA hybridization/subtraction and PCR amplification, individual fragments (DP2) were isolated from two breast cancer patients (see "Materials and Methods"). The DP2 fragments were subcloned into the pUC118 vector, and the inserts were amplified by PCR. Twelve different-sized inserts were selected from each modified RDA and used as probes for the master amplicon Southern blot. Two probes, *BR50* and *BR254*, isolated from two patients, were identified as candidate probes for additional study. In this report, we focus on presenting the work that has been done by probe *BR50*.

Probe *BR50* was selected from the DP2 isolated from breast cancer patient no. 14's biopsy by the modified RDA technique (Fig. 1a) because it hybridized a band of much greater intensity in the tester




Fig. 1. a, the agarose gel electrophoresis of the final difference products isolated by a modified RDA technique from the breast cancer biopsy of patient no. 14. Lane M, *Hae*III  $\phi$ 174 DNA size markers in bp. Lane A, DNA fragments from which *BR50* was isolated. b, the amplicon Southern Blot results for *BR50*. Left lane, probe *BR50* hybridizes to itself as a positive control. In Lanes T and D, probe *BR50* hybridizes with 2  $\mu\text{g}$  of tester (tumor) and driver (normal) master amplicon DNA prepared from breast cancer patient no. 14. The tester master amplicon DNA displays a much heavier hybridized band than the driver master amplicon DNA. The picture below the Southern blot is the tester and driver amplicon agarose gel electrophoresis before transferring it onto the blot membrane, which served as the DNA quantitative control.

amplicon than that in the driver amplicon (Fig. 1b). To confirm the differences observed in the tester and driver amplicons, a Southern analysis was performed on patient no. 14's tumor and matched normal genomic DNAs. Six  $\mu\text{g}$  of each DNA were cleaved with the *MspI* enzyme and hybridized by probe *BR50*. The results showed that in the tumor DNA, the probe hybridized a lower band,  $\sim 1$  kbp long, of much greater intensity than an upper band, which was  $\sim 2$  kbp in length. In the normal DNA, just the opposite occurred (Fig. 2). Because the sizes of the upper and lower bands in the tumor and normal control DNAs were the same, the only reasonable explanation causing uneven hybridization intensities is DNA hypomethylation in the tumor cells. To examine whether the event also existed in other breast cancer patients, paired tumor and normal DNAs isolated from additional breast cancer biopsies were cleaved with *MspI* and subjected to Southern analysis. The results showed that of 10 samples tested, 4 had similar hybridization patterns to those of patient no. 14 (Fig. 2). It is notable that in the normal DNAs of patient nos. 3, 4, and 5, more than one upper band was evident. We believe this can be attributed to partial DNA demethylation, instead of incomplete enzymatic digestion. This is because the Southern membrane was reblotted by a control probe, which was a background probe isolated along with probe *BR50*, and only a single hybridized band was displayed in each lane (Fig. 2).

**BR50 Also Detected Altered Methylation Patterns in Ovarian Cancer.** To examine whether the hypomethylation event also occurred in human ovarian cancer, paired DNA samples isolated from eight ovarian cancer patients were analyzed by probe *BR50*. The DNAs were cleaved with *MspI* and hybridized with probe *BR50* in a Southern blot experiment. The results demonstrated that of eight patients tested, four displayed similar hybridization patterns to those observed in the breast cancer samples. In the tumor DNAs, the lower band was heavily hybridized by the probe, whereas in the normal control DNAs, a lower and upper band were hybridized. The completion of DNA digestion was confirmed by the same control probe used before, which only hybridized a single band in each lane (Fig. 3). Thus, *BR50* also detected altered DNA methylation in ovarian cancer.




Fig. 2. The breast cancer genomic DNA Southern blot for probe *BR50*. Left lane of each blot, probe *BR50* hybridizes to itself as a positive control. *BR50* hybridizes with *MspI*-digested 6  $\mu\text{g}$  of original tumor (T) and matched normal (N) genomic DNAs isolated from patient no. 14 and other breast cancer patients. The number for each patient tested is listed above the bracket. Similar hypomethylation patterns in patient no. 14 and the other patients are observed. The control probe in the lower section served as an indicator of complete enzymatic digestion.




Fig. 3. The different methylation patterns displayed by probe *BR50* in ovarian cancer. The number for each patient is listed above the bracket. Lanes T and N include 6  $\mu\text{g}$  of tumor DNA and normal DNA digested with *MspI*, respectively. Tumor and matched normal DNAs were cleaved with *MspI* and probed by *BR50* in a Southern blot experiment. Methyl-differential patterns are detected by *BR50*. The completion of the enzyme digestion was confirmed by the control probe, which only hybridized a single band in each lane.

**Sequencing and Chromosome Assignment of Probe *BR50*.** DNA sequencing found that *BR50* contains 1005 bps, with a CG content of 58% (Fig. 4a). The DNA fragment has a GGCCGG sequence on one end and CCGG sequence on the other end. Because *MspI* is sensitive to GGC<sup>m</sup>CCG and not sensitive to CC<sup>m</sup>GG sequences, it is conceivable that the GGCCGG sequence was methylated in normal breast tissue DNA while being hypomethylated in tumor DNA. This prediction probably holds true because all of the candidate probes, including probe *BR254* and subsequent probes isolated from breast cancer biopsies, have one end terminating with a GGCCGG sequence and the other with a CCGG sequence (data not shown). A homologue search of the NIH GenBank discovered that *BR50* is not homologous to any existing sequences.<sup>4</sup> The chromosome assignment determined by monochromosomal human/rodent somatic cell hybrid mapping panel #2 established its location on chromosome 3 (data not shown). The fine chromosome position of *BR50* was analyzed by PCR amplification using GeneBridge 4 Radiation Hybrid Panel as templates. The top and bottom strand primers for *BR50* are 5'-ACCAGATGGAGGCAGTTGAC-3' and 5'-AAGTGGGTGCTCTTTCTGTG-3', respectively. The result obtained from radiation hybrid mapping suggests that *BR50* is placed 4.29 cR below the adjacent STS, AFMB362WB9, which is 179.84 cR from the top of the chromosome 3 linkage group. This result confirmed that *BR50* is proximally located on 3p12-14.

**Search for the Coding Regions by Probe *BR50*.** On the basis of our preliminary analysis, *BR50* was an interesting probe to be used for an adjacent gene search because it was differentially methylated in some breast and ovarian cancer samples tested, although the sample size was small. *BR50* is a genomic fragment, and consequently the chances that it encodes a polypeptide are slim because a majority of human genomic DNA sequences are noncoding sequences. As a result, we decided that the first step in searching for a gene should be to isolate a longer DNA piece from a human genomic DNA library,

<sup>4</sup> GenBank accession numbers: *BR50*, U78781; *TSP50*, AF100707.

**a.**

CCGGAGGCAGGCACAGGACTCGGGAGGGACGCTGCCAGCTCTCTGGGTGCTGAGTTTACAAGGCTG  
 CATTTCATGATTTTCAATAGACCTGTGATGGTCTGTGCCAGTGCTGGGGACACAGAAGAGTCAAAC  
 CTGGCTCTGACCTGGACCTGGATCATCACGTGACAGGGAGGAGAGCGGATCCAGGCTGATGAGGAA  
 AGCGCATGACATGGGGTCTTAGGAGCAGTGAGGGGACAGGCCATGGCCAAAGGCCCGCCATGGAA  
 GCTGAGGACTCTGGCACCAGATGGAGGCAGTTGACGGACCTCTGCCCTTGGGGTCAAACCCATGGG  
 CTCTCATACATAGGGGTGAAAAGGCCATCTATTTATGCGAATTTTCCCATGTGGCCAGGCAG  
 CAGAAGTCCAGAGGGGTAGGGGCCACTCAGGGTCCACACAGAACAGCAGTTGCTGAAGACTGGGGAA  
 GTCAGGCTTAGGCTCCACCTGCCCTTCCCTGACATGGGGCCACCCTAGCCCTTTTATGGGCGAGG  
 CCTGGCTGCTGGTGGTGGAAATAACATCTGACTCCAGTGGGTGCTGTGCACCGTCTCCAGACAGGA  
 GACAGAGACAGAGGGTCAAAGTTCACATATGGCTCTTTGGGGCAATGAAATGCTGTGTTTACGCTC  
 TTGCCAGAAATCAGCCAAAGTCAAGGAAAGCCTGACTCCACAGTTATCAGAGAAAGAGCACCCAC  
 TTCCAGCCAGACAGCTGCACCCAGCTGGGTCTGGCAGCCCGAGCTTCAGCTGGGCGGTATG  
 TTCCAGGCCCCGATCATCTGACCCATAATATCACCCCTTACACCCCTCCACTTTCTGCGGGAG  
 CCACCCGAACCTTTGAATGGGGGAGATCTGGAGGCTCTGCAATTTTCAGTGTAAACTGCCTGGA  
 GTTCCCACTTACCCTCATCTGGTTTACCTGTGGACTCCCAACAGAGCAGGCCAGGAAACCGCG  
 GGCTCTGAGGCGCG

**b.**

-59 gtcgtggggcgcc

actgggagcgccctccggagagacgcagctcggtgccacccccggg

1 **atgggtcgctggtgccagaccgtcgcgcgggcagcgccccggg**  
 M G R W C Q T V A R G Q R P R

46 acgtctgccccctcccgcgcggtgccctgctgctgctctctg  
 T S A P S R A G A L L L L L L L

91 ttgctgaggtctgcaggttgctggggcgcaggggaagccccggg  
 L L R S A G C W G A G E A P G

136 gcgctgtccactgctgatcccgcgaccagagcgtccagtgtgtc  
 A L S T A D P A D Q S V Q C V

181 cccaaggccactgtccttccagccgctcgccttctctggcag  
 P K A T C P S S R P R L L W Q

226 accccgaccaccagacactgccctcgaccaccatggagaccaca  
 T P T T Q T L P S T T M E T Q

271 ttccagtttctgaaggcaagtcgaccataccgctcctgtggc  
 F P V S E G K V D P Y R S C G

316 *tttccctacgagcaggaccccaccctcagggaccagaagccgtg*  
*F S Y E Q D P T L R D P E A V*

361 *gctcggcggtggccctggatggtcagcgtgcccccaatggcaca*  
*A R R W P W M V S V R A N G T*

406 *cacatctgtgcccgcaccatcattgctcccagtggtgctgact*  
*H I C A G T I I A S Q W V L T*

451 *gtggccactgcctgatctggcgtgatgttatctactcagtgagg*  
*V A H C L I W R D V I Y S V R*

496 *gtggggagtcctggattgaccagatgacgcagaccgctccgat*  
*V G S P W I D Q M T Q T A S D*

541 *gtccccgtgctccaggtcatcatgcatagcaggtaccgggcccag*  
*V P V L Q V I M H S R Y R A Q*

586 *cggttctggtcctgggtggccaggccaacgacatcgccctcctc*  
*R F W S W V G Q A N D I G L L*

631 *aagctcaagcaggaactcaagtacagcaattacgtgcccaccatc*  
*K L K Q E L K Y S N Y V R P I*

676 *tgctgcctggcagcagactatgtgtgaaggaccattcccgtgctc*  
*C L P G T D Y V L K D H S R C*

721 *actgtgacgggctgggactttccaaggctgacggcatgtggcct*  
*T V T G W G L S K A D G M W P*

766 *cagttccggaccattcaggagaaggaagtcacatcctgaacaac*  
*Q F R T I Q E K E V I I L N N*

811 *aaagagtgtgacaatttctaccacaacttcacaaaatccccact*  
*K E C D N F Y H N F T K I P T*

856 *ctggttcagatcatcaagtcaccagatgatgtgtgaggaggaccc*  
*L V Q I I K S Q M M C A E D T*

901 *cacagggagaagttctgctatgagctaaactggagacccttggtc*  
*H R E K F C Y E L T G E P L V*

946 *tgctccatggagggcacgtggtacctggtgggattggtgagctgg*  
*C S M E G T W Y L V G L V S W*

991 *ggtgcaggctgccagaagagcagggcccaaccatctacctacag*  
*G A G C Q K S E A P P I Y L Q*

1036 *gtctcctcctacaaacactggatctgggactgcctcaacgggcag*  
*V S S Y Q H W I W D C L N G Q*

1081 *gccctggccctgccagccccatccaggaccctgctcctggcactc*  
*A L A L P A P S R T L L L A L*

1126 *ccaactgcccctcagcctccttgctgcctctgactcctgtgtgcc*  
*P L P L S L L A A L \**

1171 *tcctcacttg*

Fig. 4. *a*, the sequence of the genomic DNA probe BR50. *b*, nucleotide and predicted amino acid sequences of the human TSP50 gene. The adenine at the ATG (bold-type) initial codon is considered the number 1 nucleotide. The stop codon, TGA, is also in *boldface*. The sequences of exon BR50-44 and BR50-45 are in *italics*.

with the hope that it may contain exon(s). It is well known that DNA methylation sites can be near genes (18); therefore, we decided to screen a human placenta genomic phage library, EMBL3 SP6/T7 (Clontech, Inc.), where the insertion sizes were relatively small (9–28 kbp). For this purpose,  $2 \times 10^6$  plaques derived from the library were screened by probe *BR50*. As a result, a 17-kbp length clone was isolated. To obtain the sequence information, the DNA clone was released from the phage DNA arms by restriction enzyme *SstI* cleavage, which generated eight DNA fragments. All eight fragments were subcloned into pUC118 plasmids. The fragments smaller than 1 kbp were completely sequenced, whereas the fragments larger than 1 kbp were partially sequenced from both the plasmid and insert junctions. A homologue search of the NIH GenBank revealed two exons, *BR50-44* and *BR50-45*, which contained 112 and 132 nucleotides, respectively. Both exons encoded polypeptides that were ~50% identifiable to several mammalian proteases, such as serine proteases and trypsinases. The *BR50-45* sequence was found 142 bp upstream of the *BR50* sequence.

Because we did not know the exact positions of the two exons in the 17-kbp fragment, it was possible that other exon(s) might lay between them. To gain a longer coding sequence, we designed four oligomers (A, B, C, and D), based on the sequence information of both exons, to perform PCR. Oligomer A (5'-CCTGGATGGTCAGCGTG-3') and B (5'-CTGGGAGGCAATGATGGT-3'), which were on the complementary strand, were based on the sequence information of *BR-44*; and C (5'-CTGGAGAGCCCTTGGTCT-3') and D (5'-CAGTGTG-GTAGGAGGAG-3'), which were on the complementary strand, were based on the sequence information of *BR-45*. A strategy using four different combinations of oligomer pairs was used to perform PCR by using the Human Universal cDNA Library Panel (Clontech, Inc.). A PCR product, which was about 700 bp in length, was generated from one oligomer combination (A/D, 5'-CCTGGATGGTCAGCGTG-3'/5'-CAGTGTGTTGGTAGGAGGAG-3'). This PCR product was directly sequenced. Combining the sequence information of the PCR product and the two exons, we obtained a cDNA fragment that contained 974 bps. The DNA homologue search of the NIH GenBank revealed again that it coded for a protease-like protein, and the overall identity was ~40%.

**The Candidate Gene Is Highly and Specifically Expressed in Human Testes.** To obtain a full-length cDNA, it is critical to use the right cDNA library where the gene of interest is expressed. Thus, two Human Multiple Tissue Northern blot panels, MTN and MTN II, containing 16 different tissue mRNAs (Clontech, Inc.), were used to test the expression of the candidate gene by using the 700-bp cDNA PCR product as a probe. The results showed that there were no visible transcripts of this gene in the eight mRNAs (heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas) included in the MTN panel (data not shown). In the MTN II panel, a 1.7-kbp band was heavily hybridized by the probe exclusively in the testes mRNA as compared with the control probe, which was the human *rab6* gene (Fig. 5). These results suggested that the gene that we were searching for is a tissue-specific gene. We have named the gene *TSP50*. At this moment, the biological function(s) of the gene in human testes remains unknown.

**Isolation of the Full-length *TSP50* Gene from a Human Testes cDNA Library.** *TSP50* is highly expressed in human testes; to search for the full-length *TSP50* gene, a human testes cDNA library (Human Testis cDNA Library; Clontech, Inc.) was screened by the 700-bp *TSP50* cDNA sequence. A cDNA clone containing the probe sequence was isolated. Sequence analysis suggests that this fragment encodes a protein with 385 amino acids (Fig. 4b). There is a stop codon located at the 117th bp upstream of the first initial translation site, and there is a 125-bp untranslated region before a polyadenosine




Fig. 5. Northern blot results analyzed by the 700-bp *TSP50* fragment. The Human Multiple Tissue Northern blot panel, MTN II, containing the mRNA of eight different tissues (Clontech Inc.), was tested to determine the expression levels of the gene. Compared with the control (the human *Rab6* gene, which was evenly expressed in all tissues), *TSP50* was highly expressed in the testes tissue but not in the other tissues.

sequence. These results imply that a full-length gene has been obtained. It is also notable that the *BR50* probe sequence is located at the 3' end of the gene and is only 17 bp downstream from the polyadenosine adding signaling site. The exons *BR50-44* and *BR50-45* encode amino acids from 103 to 157 and 308 to 385, respectively (Fig. 4. b). The 3'- untranslated region before the polyadenosine site is also included in the sequence of *BR50-45*.

**DNA Methylation Status of the *TSP50* Gene in Human Testes and Other Normal Tissues.** Our studies have proven that *TSP50* is a tissue-specific gene, and the methylation patterns in its 3' region were altered in some breast and ovarian cancers. It is also known that many tissue specific genes are methylated, and this methylation may regulate their expression (22–24). To explore the possible relationship between *TSP50* gene expression and DNA methylation in different normal human tissues, Southern analysis was performed. The normal tissues tested included the testes, where *TSP50* was expressed, and bladder, blood, breast, colon, lung, kidney, placenta, and ovary samples, where *TSP50* was apparently not expressed. To perform the Southern analysis, *BR50* was used as a probe. DNAs isolated from the nine tissues were digested by *MspI* and *HpaII*, which is an isoschizomer of the *MspI* enzyme and the most popular enzyme used to study DNA methylation patterns (25). *HpaII* digestion showed that in the testes DNA, two bands, probably released from each allele by enzyme cleavage, were hybridized by the probe. However, in the DNAs of other tissues, the corresponding bands were either not hybridized or hybridized to a much smaller degree (Fig. 6a). For *MspI* cleavage, both bands were released in different tissues to various extents (Fig. 6b). Both blots used a genomic fragment that did not detect differential DNA methylation as a control to determine complete enzymatic digestion (Fig. 6). These results demonstrated that the *TSP50* gene was differentially methylated in various human tissues. In general, DNA demethylation in the testes is correlated with high levels of gene expression. Conversely, DNA methylation is correlated with gene




Fig. 6. DNA methylation status of the *TSP50* gene in nine normal human tissues examined by Southern blot. In *a* and *b*, the results obtained from *HpaII* and *MspI* digestion, respectively, are shown. Six  $\mu$ g of DNA isolated from each tissue were cleaved by the enzymes and subjected to Southern analysis by probe *BR50*. *a*, the results show that two bands, which are approximately 1 and 2 kbp in length, were released by *HpaII* only in the testes tissue. *b*, a 2-kbp band was released by *MspI* in most tissues. In *a* and *b*, the control probe hybridized a single band in the DNA of each tissue, which provides proof of complete enzymatic digestion.

silencing in the bladder, blood, breast, colon, lung, kidney, placenta, and ovary tissues.

***TSP50* Was Differentially Expressed in Some Breast Cancer Tissues.** Preliminary results demonstrated that *TSP50* was differentially methylated in 40% of the breast cancer tissues tested. This suggested that it could also be differentially expressed in cancer. To test this possibility, RT-PCR was carried out to determine *TSP50* expression levels in 18 paired breast cancer tissues. Our findings showed that *TSP50* PCR products were generated in five tumor tissues, whereas in their normal controls, they were not visible relative to the control gene,  $\beta$ -actin (Fig. 7). Products generated from the five patients were gel purified and sequenced. DNA sequence analysis confirmed that the PCR products synthesized were the *TSP50* gene (data not shown). Therefore, among the 18 paired samples tested, 28% of the tissues expressed the *TSP50* gene. At this moment, we cannot answer the question of whether activation of the *TSP50* gene in cancer is a consequence or a causal factor of neoplastic growth. To find the truth, it will be necessary to perform *in vitro* cellular transformation and *in vivo* tumor induction assays.

## DISCUSSION

A modified RDA technique was used to study genetic alterations by using breast cancer biopsies as a working model system. As a result, two hypomethylated genomic DNA fragments were successfully iso-

lated. The extensive study of one of the two fragments, *BR50*, is the subject of this report.

It has been reported that aberrant DNA methylations occur constantly in human tumors (9–12, 24, 26). DNA hypomethylations could activate oncogenes, whereas DNA hypermethylation could inactivate recessive oncogenes. Both events could result in neoplastic growth (27–35). The correlation between aberrant DNA methylations and malignancies suggests that differentially methylated fragments in tumors isolated by a modified RDA technique could be a valuable tool in the search for genes that might be related to cancer development. *BR50* was considered to hold such value because it not only detected DNA hypomethylations in the original breast cancer tissues from which it was isolated but also detected DNA hypomethylations in other breast and ovarian cancer samples.

Our first step in processing the gene search was to screen a human genomic phage library. A 17-kbp DNA fragment was isolated, and sequence analysis suggested that this fragment contained at least two exons that were homologous to mammalian proteases. The sequencing information of the exons led to the discovery of a 974-bp gene fragment from a human cDNA library panel by PCR amplification. To obtain a full-length gene, a Northern evaluation on 16 different types of human RNAs was performed. The results demonstrated that the target gene was specifically expressed in human testes tissue. This information secured the isolation of an intact gene, *TSP50*, by screening a human testes cDNA library. The sequence analysis revealed that the *TSP50* gene encodes a protein that shares ~40% identity with mammalian proteases, such as human trypsin or mouse serine protease. This would suggest that the product of the *TSP50* gene is a protease. However, at this point, we do not know the physiological function(s) of this protease. One may assume, though, that it could be a component in the human reproductive pathway due to it being solely expressed in the testes.

It is common knowledge that the expression of many tissue-specific genes is regulated by DNA methylations, which usually modify the promoter, or sometimes, 3' regions (3, 4, 22–24, 36). Our preliminary results, although only obtained from analyzing the DNA methylation status of the 3' flanking region of the gene, have proven that *TSP50* is one of those tissue-specific genes. It will be interesting to discover whether the promoter region of the gene is also methylated when the corresponding sequence information is available. The *HpaII* and *MspI* methylation-sensitive Southern analysis of the 3' region of the *TSP50* gene demonstrated that, in *HpaII*-digested DNAs, probe *BR50* hybridized two bands in the testes tissue but none in the other samples. The lower band, which was the same size as the probe, represented the unmethylated DNA pattern, whereas the upper band obviously con-




Fig. 7. The results of RT-PCR for *TSP50* differentially expressed in five breast cancer and normal control tissues. Lane MW, *HaeIII*  $\phi$ 174 markers in bp. The  $\beta$ -actin and *TSP50* lanes served as positive controls; they were generated by using cDNA prepared from testes tissue RNA. Lane  $\beta$ -actin + *TSP50* contains simultaneously generated *TSP50* and  $\beta$ -actin from testes cDNA. The number for each patient tested is listed above the bracket. T and N, tumor and normal tissues, respectively.

tained the internal *HpaII* recognition site(s), which remained methylated. In *MspI*-digested DNAs, the upper band was dominant in most tissues, whereas in the testes, the lower band was dominant. These results suggest that the GGCCGG end of *BR50* was methylated in other tissues but not in the testes. The DNA methylation patterns observed in both blots are probably allelic orientated. It seems that DNA hypomethylation was accompanied by the expression of the gene in the testes, and conversely, DNA hypermethylation was accompanied by the silencing of the gene in other tissues. The correlation between DNA methylation and gene expression provided additional proof that DNA methylation could be an important mechanism in governing the expression of the genes in various differentiated human cells (12, 37, 38). In addition, the differential expression of the *TSP50* gene has been tested in 18 paired breast cancer biopsies. Our findings have shown that this gene was activated in five cancer samples. In the near future, more samples from different types of cancer will be examined, and the possibility that the *TSP50* gene product might be one of the factors that stimulate human cancer will be further explored.

Recently, by using the same technique, DNA fragments that represent DNA amplifications, deletions, and rearrangements were also obtained (data not shown). Hopefully, this technique will lead to the discovery of additional novel genes that may be related to cancer development. On the basis of our experience, the process of isolating the *TSP50* gene was made considerably easier by the modified technology, where the *MspI* enzyme was used as the master enzyme. The ability of *MspI* to recognize GC-rich sequences and its sensitivity to DNA methylation (17, 18) apparently accelerated our gene search. Furthermore, the double enzyme cleavage strategy provides another unique and efficient feature for this technique because ~40% of a human genome can theoretically be analyzed by a single master enzyme when it is combined with a different partner enzyme.

## ACKNOWLEDGMENTS

We thank Craig Gawel for technical assistance and James Duffy for manuscript preparation.

## REFERENCES

- Shaw, D. J., Chaudhary, S., Rundle, S. A., Crow, S., Brook, J. D., Harper, P. S., and Harley, H. A study of DNA methylation in myotonic dystrophy. *J. Med. Genet.*, **30**: 189–192, 1993.
- Laird, P. W., and Jaenisch, R. DNA methylation and cancer. *Hum. Mol. Genet.*, **3**: 1487–1485, 1994.
- Riggs, D. A. 5-Methylcytosine, gene regulation, and cancer. In: J. P. Jost and H. P. Saluz (eds.), *DNA Methylation: Molecular Biology and Biological Significance*, pp. 1–30. Basel, Switzerland: Birkhauser Verlag, 1993.
- Spruck, H. C., III, Rideout, M. W., III, and Jones, A. P. DNA methylation and cancer. In: J. P. Jost and H. P. Saluz (eds.), *DNA Methylation: Molecular Biology and Biological Significance*, pp. 487–509. Basel, Switzerland: Birkhauser Verlag, 1993.
- Laird, P. W., Jackson-Grusby, L., Fazeli, A., Dickinson, S. L., Jung, W. E., Li, E., Weinberg, R. A., and Jaenisch, R. Suppression of intestinal neoplasia by DNA hypomethylation. *Cell*, **81**: 197–205, 1995.
- Counts, J. L., and Goodman, J. I. Alteration in DNA methylation may play a variety of roles in carcinogenesis. *Cell*, **83**: 13–15, 1995.
- Baylin, S. B., Herman, J. M., Graff, J. R., Vertino, P. M., and Issa, J.-P. Alterations in DNA methylation: A fundamental aspect of neoplasia. *Adv. Cancer Res.*, **72**: 141–196, 1998.
- Bird, P. A. CpG islands as gene markers in the vertebrate nucleus. *Trends Genet.*, **3**: 342–346, 1987.
- Larsen, F., Gunderson, G., Lopez, R., and Prydz, H. CpG island as gene markers in the human genome. *Genomics*, **13**: 1095–1107, 1992.
- Adams, R. L., and Buron, R. H. DNA methylation in eukaryotes. *CRC Crit Rev. Biochem.*, **13**: 349–384, 1982.
- Antequera, F., and Bird, P. A. CpG islands. In: J. P. Jost and H. P. Saluz (eds.), *DNA Methylation: Molecular Biology and Biological Significance*, pp. 169–185. Basel, Switzerland: Birkhauser Verlag, 1993.
- Bird, P. A. CpG-rich islands and the function of DNA methylation. *Nature (Lond.)*, **321**: 209–213, 1986.
- Gardiner, K. Base composition and gene distribution: critical patterns in mammalian genome organization. *Trends Genet.*, **12**: 519–524, 1996.
- Lisitsyn, N., Lisitsyn, N., and Wigler, M. Cloning the differences between two complex genomes. *Science (Washington DC)*, **259**: 946–951, 1993.
- Cedar, H., Solage, A., Glaser, G., and Razin, A. Direct detection of methylated cytosine in DNA by use of the restriction enzyme. *Msp I*. *Nucleic Acids Res.*, **6**: 2125–2133, 1979.
- Busslinger, M., deBoer, E., Wright, S., Grosveld, F. G., and Flavell, R. A. The sequence GGCCGG is resistant to *MspI* cleavage. *Nucleic Acids Res.*, **11**: 3559–3569, 1983.
- Antequera, F., Boyes, J., and Bird, A. High levels of *de novo* methylation and altered chromatin structure at CpG islands in cell lines. *Cell*, **62**: 503–514, 1990.
- Weng, A., Engler, P., and Storb, U. The bulk chromatin structure of a murine transgene does not vary with its transcriptional or DNA methylation status. *Mol. Cell. Biol.*, **15**: 572–579, 1995.
- Bishop, D. T., Williamson, A. J., and Skolnick, H. M. A model for restriction length distributions. *Am. J. Hum. Genet.*, **35**: 795–815, 1983.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. In: N. Ford, C. Nolan, and M. Ferguson (eds.), *Molecular Cloning Manual*, pp. 9.16–9.19. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
- Walter, M. A., Spillett, D. J., Thomas, P., Weissenbach, J., and Goodfellow, P. N. A method for constructing radiation hybrid maps of whole genomes. *Nat. Genet.*, **7**: 22–28, 1994.
- Bird, A. Gene number, noise reduction and biological complexity. *Trends Genet.*, **11**: 94–100, 1995.
- Kass, S. U., Pruss, D., and Wolffe, A. P. How does DNA methylation repress transcription? *Trends Genet.*, **13**: 444–449, 1997.
- Siegfried, Z., and Cedar, H. DNA methylation: a molecular lock. *Curr. Biol.*, **7**: R305–R307, 1997.
- Nelson, M., and McClelland, M. Site-specific methylation: effect on DNA methylation methyltransferases and restriction endonucleases. *Nucleic Acids Res.*, **19**: 2045–2071, 1991.
- Yeivin, A., and Razin, A. Gene methylation patterns and expression. In: J. P. Jost and H. P. Saluz (eds.), *DNA Methylation: Molecular Biology and Biological Significance*, pp. 523–568. Basel, Switzerland: Birkhauser Verlag, 1993.
- Cheah, M. S., Wallace, C. D., and Hoffman, R. M. Hypomethylation of DNA in human cancer cells: a site-specific change in the *c-myc* oncogene. *J. Natl. Cancer Inst.*, **73**: 1057–1065, 1984.
- Hanada, M., Delia, D., Aiello, A., Stadtmayer, E., and Reed, J. C. *bcl-2* gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. *Blood*, **82**: 1820–1828, 1993.
- Ray, J. S., Harbison, M. L., McClain, R. M., and Goodman, J. I. Alterations in the methylation status and expression of the *raf* oncogene in phenobarbital-induced and spontaneous B6C3F1 mouse liver tumor. *Mol. Carcinog.*, **9**: 155–166, 1994.
- Vorce, R. L., and Goodman, J. I. Altered methylation of *ras* oncogenes in benzidine-induced B6C3F1 mouse liver tumors. *Toxicol. Appl. Pharmacol.*, **100**: 398–410, 1989.
- Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D.-S. R., Gnarr, J. R., Linehan, M., and Baylin, S. B. Silencing of the *VHL* tumor-suppressor gene by DNA methylation in renal carcinoma. *Proc. Natl. Acad. Sci. USA*, **91**: 9700–9704, 1994.
- Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor *p16/CDKN2/MTS1* in human cancers. *Nat. Med.*, **1**: 686–692, 1995.
- Herman, J. G., Jen, J., Merlo, A., and Baylin, S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for *p15<sup>INK4B1</sup>*. *Cancer Res.*, **56**: 722–727, 1996.
- Graff, J. R., Herman, J. G., Lapidus, R. G., Chopra, H., Xu, R., Jarrard, F., Isaacs, W. B., Pitha, P. M., Davidson, N. E., and Baylin, S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. *Cancer Res.*, **55**: 5195–5199, 1995.
- Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J.-P. Alterations in DNA methylation: a fundamental aspect of neoplasia. *Adv. Cancer Res.*, **72**: 141–196, 1998.
- Graff, J. R., Herman, J. G., Myohanen, S., Baylin, S. B., and Vertino, P. M. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in *de novo* methylation. *J. Biol. Chem.*, **272**: 22322–22329, 1997.
- Razin, A., and Kafri, T. DNA methylation from embryo to adult. *Prog. Nucleic Acid Res. Mol. Biol.*, **48**: 53–58, 1994.
- Martienssen, R. A., and Richards, E. J. DNA methylation in eukaryotes. *Curr. Opin. Genet. Dev.*, **5**: 234–242, 1995.

DO NOT FOLD

FOR OFFICE USE ONLY

## Abstract Form

# 91st ANNUAL MEETING

April 1-5, 2000

The Moscone Center • San Francisco, CA

Deadline: November 1, 1999

Enclose:

- Original abstract form (This form must be filled out and signed completely)
- Check for US\$40 payable to AACR, Inc. OR authorization to charge US\$40 to credit card (see Item 8 below)
- A completed and signed original of the Copyright Transfer/Disclosure form

1. Category and Subclassification (see pages 10-12): Type the five-character code in the blocks provided.

B	L	3	-	0	7
---	---	---	---	---	---

2. Abstract is SPONSORED by: 3903 Member No.  
(See Directory of Members for Member No.)

Daniel R. Budman MD Name  
(Please Print)  
Division of Oncology Address  
North Shore University Hospital  
Manhasset NY City, State  
11030 Zip/Postal Code USA Country  
516 562 8958 Telephone No. 516 562 8958 FAX No.  
budman@nshs.edu E-Mail Address

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein.

[Signature] Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus Member, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on page 5.)

\_\_\_\_\_  
(Please Print) Name  
\_\_\_\_\_  
Signature Member No.

5. Eligibility for Young Investigator Awards (American and International)
- A. The PRESENTER of this abstract is a medical or graduate student, medical resident, or postdoctoral or clinical fellow.
  - B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see page 7).
  - C. The PRESENTER of this abstract is a full-time faculty member at a Historically Black College or University (HBCU).

A NOVEL SERINE PROTEASE, TSP50, IS ACTIVATED IN BREAST CANCER CELLS. L. M. Yuan, J. D. Shan, D. De Risi, J. Broome, J. Lovecchio, D. Gal, V. Vinciguerra, D. R. Budman and H. P. Xu. *North Shore-Long Island Jewish Health System, New York University School of Medicine, Manhasset, NY 11030.*

A modified Representational Difference Analysis technique was employed to study altered DNA methylation in human breast cancer. This has led to the discovery of a novel gene, TSP50. TSP50 exhibited a 40% identity to various serine proteases, such as prostaticin, tryptase, and hepsin. The multiple sequence alignment showed that the TSP50 protein (tsp50p) contains two of the three common "catalytic triads," Aspartate (electrophile) and Histidine (base), present in many serine proteases. However, the Serine (nucleophile) triad has been replaced by a Threonine residue that is surrounded with conserved residues including a crucial glycine. Therefore, tsp50p could be a new type of serine protease, with a distinctive mechanism of action. Northern analysis found that the TSP50 gene was highly, and exclusively expressed in human testes, but not in other normal tissues. RT-PCR analysis of paired breast cancer samples demonstrated that the TSP50 gene was activated in some tumor specimens. Most important, the results obtained from *in situ* hybridization experiments showed that the activation of this gene occurred in the advanced tumor cells. These findings indicate that abnormal expression of the TSP50 gene may be related to breast cancer progression.

Type abstract within black lines. See sample abstract.

6. Abstract to be PRESENTED by: \_\_\_\_\_ Member No.  
(If an AACR Member.)

Liming Yuan Name  
(Please Print)  
Rm 217, Research Building Address  
350 Community Drive  
Manhasset, NY City, State  
11364 Zip/Postal Code USA Country  
516 562-1155 Telephone No. 516 562-1022 FAX No.  
lyuan@nshs.edu E-Mail Address

7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 2000 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original of the Copyright Transfer/Disclosure Form.

[Signature] Signature of PRESENTER

8. Payment of US\$40 Abstract Submission Fee.  
 Check is enclosed. Please list name of PRESENTER on the check.  
 I authorize you to charge my credit card for the abstract submission fee.  
 VISA  MasterCard  American Express

\_\_\_\_\_  
Card No. Expiration Date  
\_\_\_\_\_  
Cardholder Name (PRINT) Signature

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US\$40 which will be billed to the SPONSOR.

LAW OFFICES OF  
**KENYON & KENYON**  
ONE BROADWAY

WASHINGTON, D.C. OFFICE  
1500 K STREET, N.W., SUITE 700  
WASHINGTON, D.C. 20005-1257  
TEL. (202) 220-4200  
FAX. (202) 220-4201

NEW YORK, NY 10004-1050  
TEL. (212) 425-7200  
FAX. (212) 425-5288

FRANKFURT OFFICE  
SCHILLERSTRASSE 19-25  
60313 FRANKFURT AM MAIN  
FEDERAL REPUBLIC OF GERMANY  
TEL. (49) (69) 97 58 05 0  
FAX. (49) (69) 97 58 05 99

SILICON VALLEY OFFICE  
RIVERPARK TOWERS, SUITE 600  
333 W. SAN CARLOS ST.  
SAN JOSE, CA 95110-2731  
TEL. (408) 975-7500  
FAX. (408) 975-7501

October 7, 1999

WWW.KENYON.COM  
DIRECT DIAL: 212-908-6204  
EMAIL: LCASSON@KENYON.COM

*Confidential*

Dr. Hao-Peng Xu Duffy  
North Shore University Hospital  
R132 Research Building  
300 Community Drive  
Manhasset, NY 11030

Re: Identification of Differentially Methylated and Mutated Nucleic Acids  
Our Matter 52494/190376

Dear Dr. Duffy:


We enclose copies of the PCT application, Transmittal Letter and Appointment of Agent which were filed in the United States Receiving Office on September 28, 1999. The specification and claims are equivalent to U.S. Ser. No. 09/345,881, filed June 30, 1999. The PCT application was timely filed before the one year anniversary of the filing of U.S. Ser. No. 09/163,951, filed September 30, 1998.

If you have any questions in this matter, please let us know.

Sincerely,

Kenyon & Kenyon

By:

  
Lawrence P. Casson  
Legal Intern

Enclosures

cc: Susan F. Zinder, Esq.  
Robert Bienkowski, Ph.D.  
Stuart J. Sinder, Esq. (w/o enc.)  
Estelle J. Tsevdos, Esq. (w/o enc.)  
Robin A. Chadwick, Esq. (w/o enc.)

## Curriculum Vitae

Prepared 15 October 2000

**Name:** Hao-peng Xu Duffy, Ph.D.  
**Office Address:** R132 Research Building, 350 Community Drive, Manhasset, NY 11030  
**Office Phone:** (516)-562-1638

### Education:

1978 BS Beijing University  
 1982 M.S. The Academy of Medical Science, Beijing, China.  
 1990 Ph.D. State University at Stony Brook/Cold Spring Harbor Laboratory

### Postdoctoral Training:

1991-1992 Cold Spring Harbor Laboratory

### Research Fellowships:

1982-1985 Research Assistant, Institute of Basic Medical Research, General Hospital, Beijing, China.  
 1985-1986 Visiting Scientist, Wistar Institute, University of Pennsylvania.  
 1986-1987 Visiting Scientist, Department of Molecular Biology and Biochemistry, State University of New York at Stony Brook.

### Academic Appointments:

1986 Assistant Professor, Institute of Basic Medical Research, General Hospital, Beijing, China.  
 1992-1995 Staff Associate, Laboratory of Dr. Michael Wigler at Cold Spring Harbor Laboratory.  
 1995-Present Director, Molecular Oncology Laboratory

### Grants:

1. The Lauri Strauss Leukemia Foundation: (1997-1999) Ambassador Felix Schnyder Memorial Fund Grant for "Study of Genomic Lesions in Chronic Lymphocytic Leukemia". Total amount \$60,000
2. The American Cancer Society (ACS): (1 Jan. 1998-31 Dec. 1999) Research Project Grant (#RPG-98-040-01-CNE) for "Study of DNA Methylation in Breast Cancer". Total amount \$200,000. This grant was returned to ACS due to overlapping with the DOD grant.
3. Department of Defense (DOD) Medical Research and Material Command (USAMRMC): Breast Cancer Research Program Grant (DAMD17-97-7070, 1 Oct. 1997-31 Sep 2000) for "The Use of a New Technique to Study DNA Methylation

in Breast Cancer". Total amount \$300,000.

4. Department of Defense (DOD) Medical Research and Material Command (USAMRMC): Breast Cancer Research Program Grant (2000-2003) for "Search for New Multidrug Resistant Genes by Methylation Sensitive Representational Difference Analysis (MS-RDA) in Breast Cancer". Total amount \$300,000.

#### Teaching Experience:

1987-1988 Teaching Assistant, State University of New York at Stony Brook.

#### REFERENCE:

##### Journal

1. Xu, H-P., Sun, M-C., and Chou, T-C., (1984) Purification of the nicotinic cholinergic receptor protein from the electric organ of *Torpediniforms Nacline Timilei*. *Acta Biochem. Et Biophys. Sin.* 16, 50-55.
2. Liou, C-G., Xu, H-P., and Wang, H-H., (1984) A monocloning antibody against C reaction protein. *Immuno. Bulletin*, 4, 22-23.
3. Wang, Y., Xu, H-P., Wang, X-M., Ballivet, M. and Schmidt, J., (1988) A cell type-specific enhancer drives expression of the chicken muscle acetylcholine receptor  $\alpha$ -subunit gene. *Neuron*, 1, 527-534.
4. Ballester, R., Michaeli, T., Ferguson, K., Xu, H-P., McCormick, F. and Wigler, M., (1989) Genetic analysis of mammalian GAP expressed in yeast. *Cell*, 59, 681-686.
5. Field, J., Xu, H-P., Michaeli, T., Ferguson, K., Sass, P., Wigler, M. and Colicelli, J., (1990) Mutations of the adenylyl cyclase gene that block RAS function in *Saccharomyces cerevisiae*. *Science*, 247, 464-467.
6. Xu, H-P., Riggs, M., Rodgers, L. and Wigler, M., (1990) A gene from *S. pombe* with homology to *E. Coli* RNase III blocks conjugation and sporulation when overexpression in wild type cells. *Nucl. Acids Res.* 18, 5304.
7. Xu, H-P., Wang, Y., Riggs, M., Rodgers, L. and Wigler, M., (1990) Biological activity of the mammalian RAP genes in yeast. *Cell Regul.* 18, 763-769.
8. Wang, Y., Xu, H-P., Riggs, M., Rodgers, L. and Wigler, M., (1991) *byr2*, a *Schizosaccharomyces pombe* gene encoding a protein kinase capable of partial suppression of the *ras1* mutant phenotype. *Mol. Cell Bio.* 11, 3554-3563.
9. Xu, H-P., Rajavashisth, T., Grewal, N., Jung, V., Riggs, M., Rodgers, L. and Wigler, M., (1992) A gene encoding a protein with seven zinc finger domains which acts on the sexual differentiation pathway of *Schizosaccharomyces pombe*. *Mol. Bio. Cell*, 3, 721-734
10. Neiman, A., Stevenson, B., Xu, H-P., Sprague, G. F. Jr., Herskowitz, I., Wigler, M. and Marcus, S., (1992) Functional homology of protein kinases required for sexual

- differentiation in *Schizosaccharomyces pombe* and *Saccharomyces cerevisiae* suggest a conserved signal transduction module in eukaryotic organisms. *Mol. Bio. Cell.* 4, 107-120.
11. Marcus, S., Wilger, M., **Xu, H-P.**, Ballester, R., Kawamukai, M. and Polverino, A. (1993) RAS function and protein kinase cascades. *Ciba Found Symp.* 176, 53-61.
  12. **Xu, H-P.**, White, M., Marcus, S. and Wigler, M., (1994) Concerted action of RAS and G proteins in the Sexual response pathways of fission yeast. *Mol. Cell Bio.* 14, 50-58.
  13. Chang, E., Barr, M., Wang, Y., Jung, V., **Xu, H-P.** and Wigler, M., (1994) Cooperative interaction of *S. pombe* proteins required for mating and morphogenesis. *Cell*, 79,131-141.
  14. **Xu, H-P.**, Yanak, B., Wigler M. and Gorin, M., (1996) New polymorphic marker in the vicinity of the pearl locus on mouse chromosome 13. *Mamm. Gen.* 7, 16-19.
  15. Yuan, L. M., Shan, J. D., De Risi, D., Broome, J., Lovecchio, J., Gal, D., Vinciguerra, V., and **Xu, H-P.**, (1999) Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer. *Cancer Res.* 59, 3215-3221.
  16. Shan, J.D., Mason, J.M., Yuan, L.M., Barcia, M. Porti, D., Calabro, A., Budman, D., Vinciguerra, V. and **Xu, H-P.** (2000) Rab6c, A new member of the Rab gene family, is involved in drug resistance in MCF7/AdrR cells. *Gene*, 257, 67-75.

#### Meeting Abstracts:

1. **Xu, H-P.**, and Broome, J., (1997) Methylation differential display (MDD): a new technique for identifying genes with variable patterns of methylation. Biological Methylation, FASEB summer research conferences.
2. Broome, J., and **Xu H-P.**, (1997) Differentially methylated cytosines within CpCpG triplets in human normal and tumor tissues. Biological Methylation, FASEB Summer Research Conferences.
3. Shan, J-D., Budman, D., Yuan, L-M., Calabro, A., Vinciguerra, V., **Xu, H-P.**, (1999) Thirty-Fifth Annual Meeting, American Society of Clinical Oncology.
4. Shan, J. D., Yuan, L M., Gupta, V., Allen, S., Budman, D., Vinciguerra, V., and **Xu, H-P.** (2000) A Novel Gene, *WTH3*, Was Under-Expressed in Acute Myelogenous Leukemia (AML) Patients. American Association of Cancer Research (AACR) Annual Meeting.
5. Yuan, L.M., Shan, J. D., De Risi, D., Broome, J., Lovecchio, J., Gal, D., Vinciguerra, V. and **Xu, H-P.** (2000) A Novel Gene, *TSP50*, which Could Encode a Serine Protease, is Activated in Breast Cancer. American Association of Cancer Research (AACR) Annual Meeting.
6. Shan, J.D., Mason, J.M., Yuan, L.M., Barcia, M. Porti, D., Calabro, A., Budman, D., Vinciguerra, V. and **Xu, H-P.** (2000) Involvement of a Novel Gene, *Rab6c*, in Doxorubicin Resistance of Breast Cancer Cells. American Association of Cancer Research (AACR) Annual Meeting.

7. Yuan, L.M., Shan, J.D., De Risi, D., Broome, J., Lovecchio, J., Gal, D., Vinciguerra, V. and **Xu, H-P.**, (2000) A Novel Gene, TSP50, which Could Encode a Serine Protease, is Activated in Breast Cancer. DOD Breast Cancer Research Era of Hope Meeting.
8. Shan, J.D., Yuan, L.M., Budman, D., Allen, S., Vinciguerra, V., Chiozazzi N., and **Xu, H-P.** (2000) A Novel Gene Discovered by Methylation Sensitive-Representational Difference Analysis (MS-RDA) is Involved in Multidrug Resistance. 5Th World Congress on Advances in Oncology and 3rd International Symposium on Molecular Medicine.

**Issued patent:**

**Xu, H-P.** (1999). Identification of Differentially Methylated and Mutated Nucleic Acids. #5871917

**Pending patents:**

1. **Xu, H-P.**, Shan, J-D., Yuan, L-M., Calabro, A., and Budman, D., (1998). Identification of Differentially Methylated Multiple Drug Resistant Loci.
2. **Xu, H-P.**, (1998) Identification of Differentially Methylated and Mutated Nucleic Acids. A continuation-in-part (CIP) of the issued patent. This CIP is filed for protection of a novel gene, *TSP50*, which was isolated by Methyl-Differential Display technique.

The List of Personnel Receiving Pay from the Research Effort

PI: Hao-peng Xu Duffy, Ph.D.

Postdoctoral Fellow: Jidong Shan, Ph.D.